Prostaglandin	O
E2	O
Up-regulates	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
gene	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
via	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	B-cell_type
cells	I-cell_type
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	B-protein
and	I-protein
host	I-protein
cellular	I-protein
factors	I-protein
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	B-protein
immunomodulatory	I-protein
molecule	I-protein
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	B-cell_line
,	O
a	O
Jurkat-derived	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
stably	O
transfected	O
with	O
a	O
luciferase	B-DNA
gene	I-DNA
driven	O
by	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	B-DNA
LTR	I-DNA
-mediated	O
reporter	B-DNA
gene	I-DNA
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	B-protein
messengers	I-protein
involved	O
in	O
this	O
PGE2-dependent	O
up-regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
Ca2+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV-1	B-DNA
LTR-based	I-DNA
vectors	I-DNA
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF-kappaB	B-protein
in	O
the	O
PGE2-dependent	O
activating	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB-regulated	B-DNA
luciferase	I-DNA
encoding	I-DNA
vector	I-DNA
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV-1	B-DNA
LTR	I-DNA
-driven	O
reporter	B-DNA
gene	I-DNA
activity	O
in	O
studied	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
is	O
transduced	O
via	O
the	O
EP4	B-protein
receptor	I-protein
subtype	I-protein
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	B-cell_type
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	B-cell_type
cells	I-cell_type
latently	O
infected	O
with	O
HIV-1	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

273	NULL
,	NULL
No	NULL
.	NULL

42	NULL
,	NULL
Issue	NULL
of	NULL
October	NULL
16	NULL
,	NULL
pp	NULL
.	NULL

27306-27314	NULL
,	NULL
1998	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Prostaglandin	NULL
E	NULL
,	NULL
Up-regulates	NULL
HIV-1	NULL
Long	NULL
Terminal	NULL
Repeat-driven	NULL
Gene	NULL
Activity	NULL
in	NULL
T	NULL
Cells	NULL
via	NULL
and	NULL
-Independent	NULL
Signaling	NULL
Pathways*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
October	NULL
3	NULL
,	NULL
1997	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
August	NULL
5	NULL
,	NULL
1998	NULL
)	NULL
Nancy	NULL
Dumais	NULL
}	NULL
,	NULL
Benoit	NULL
Barbeaug§	NULL
,	NULL
Martin	NULL
Olivier1|	NULL
,	NULL
and	NULL
Michel	NULL
J.	NULL
Tremblay	NULL
]	NULL
From	NULL
the	NULL
Centre	NULL
de	NULL
Recherche	NULL
en	NULL
Infectiologie	NULL
,	NULL
Centre	NULL
Hospitalier	NULL
Universitaire	NULL
de	NULL
Québec	NULL
,	NULL
Pavillon	NULL
CHUL	NULL
,	NULL
and	NULL
Département	NULL
de	NULL
Biologie	NULL
médicale	NULL
,	NULL
Faculté	NULL
de	NULL
Médecine	NULL
,	NULL
Université	NULL
Laval	NULL
,	NULL
Ste-Foy	NULL
,	NULL
Québec	NULL
GI1IV	NULL
4G2	NULL
,	NULL
Canada	NULL
Replication	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
(	NULL
HIV-1	NULL
)	NULL
is	NULL
highly	NULL
dependent	NULL
on	NULL
the	NULL
state	NULL
of	NULL
activation	NULL
of	NULL
the	NULL
infected	NULL
cells	NULL
and	NULL
is	NULL
modulated	NULL
by	NULL
interactions	NULL
between	NULL
viral	NULL
and	NULL
host	NULL
cellular	NULL
factors	NULL
.	NULL

Prostaglandin	NULL
E	NULL
,	NULL
(	NULL
PGE	NULL
,	NULL
)	NULL
,	NULL
a	NULL
pleiotropic	NULL
immunomodulatory	NULL
molecule	NULL
,	NULL
is	NULL
observed	NULL
at	NULL
elevated	NULL
levels	NULL
during	NULL
HIV-1	NULL
infection	NULL
as	NULL
well	NULL
as	NULL
during	NULL
the	NULL
course	NULL
of	NULL
other	NULL
pathogenic	NULL
infections	NULL
.	NULL

In	NULL
1G5	NULL
,	NULL
a	NULL
Jurkat-derived	NULL
T	NULL
cell	NULL
line	NULL
stably	NULL
transfected	NULL
with	NULL
a	NULL
luciferase	NULL
gene	NULL
driven	NULL
by	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
,	NULL
we	NULL
found	NULL
that	NULL
PGE	NULL
,	NULL
markedly	NULL
enhanced	NULL
HIV-1	NULL
LTR-mediated	NULL
reporter	NULL
gene	NULL
activity	NULL
.	NULL

Experiments	NULL
have	NULL
been	NULL
conducted	NULL
to	NULL
identify	NULL
second	NULL
messengers	NULL
involved	NULL
in	NULL
this	NULL
PGE	NULL
,	NULL
-dependent	NULL
up-regulating	NULL
effect	NULL
on	NULL
the	NULL
regulatory	NULL
element	NULL
of	NULL
HIV-1	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
present	NULL
evidence	NULL
indicating	NULL
that	NULL
signal	NULL
transduction	NULL
pathways	NULL
induced	NULL
by	NULL
PGE	NULL
,	NULL
necessitate	NULL
the	NULL
participation	NULL
of	NULL
cyclic	NULL
AMP	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
,	NULL
and	NULL
Ca**	NULL
.	NULL

Experiments	NULL
conducted	NULL
with	NULL
different	NULL
HIV-1	NULL
LTR-based	NULL
vectors	NULL
suggested	NULL
that	NULL
PGE	NULL
,	NULL
-mediated	NULL
activation	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
was	NULL
transduced	NULL
via	NULL
both	NULL
NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
-independent	NULL
signaling	NULL
pathways	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NF-B	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-dependent	NULL
activating	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
was	NULL
further	NULL
confirmed	NULL
using	NULL
a	NULL
«	NULL
B-regulated	NULL
luciferase	NULL
encoding	NULL
vector	NULL
and	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Results	NULL
from	NULL
Northern	NULL
blot	NULL
and	NULL
flow	NULL
cytometric	NULL
analyses	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
use	NULL
of	NULL
a	NULL
selective	NULL
antagonist	NULL
indicated	NULL
that	NULL
PGE	NULL
,	NULL
modulation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
studied	NULL
T	NULL
lymphoid	NULL
cells	NULL
is	NULL
transduced	NULL
via	NULL
the	NULL
EP	NULL
,	NULL
receptor	NULL
sub-type	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
secretion	NULL
of	NULL
PGE	NULL
,	NULL
by	NULL
macrophages	NULL
in	NULL
response	NULL
to	NULL
infection	NULL
or	NULL
inflammatory	NULL
activators	NULL
could	NULL
induce	NULL
signaling	NULL
events	NULL
resulting	NULL
in	NULL
activation	NULL
of	NULL
proviral	NULL
DNA	NULL
present	NULL
into	NULL
T	NULL
cells	NULL
latently	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

Infection	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
(	NULL
HIV-	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
Grants	NULL
MT-14438	NULL
(	NULL
to	NULL
M.	NULL
J.	NULL
T.	NULL
)	NULL
and	NULL
GR-14500	NULL
(	NULL
to	NULL
M.	NULL
J.	NULL
T.	NULL
and	NULL
M	NULL
.	NULL

O	NULL
.	NULL
)	NULL

.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7	NULL
Holds	NULL
a	NULL
Ph.D.	NULL
fellowship	NULL
from	NULL
the	NULL
Fonds	NULL
de	NULL
la	NULL
Recherche	NULL
en	NULL
Santé	NULL
du	NULL
Québec	NULL
.	NULL

§	NULL
Recipient	NULL
of	NULL
an	NULL
institutional	NULL
postdoctoral	NULL
Fellowship	NULL
from	NULL
the	NULL
Centre	NULL
de	NULL
Recherche	NULL
du	NULL
Pavillon	NULL
CHUL	NULL
.	NULL

«	NULL
These	NULL
authors	NULL
hold	NULL
scholarship	NULL
awards	NULL
from	NULL
the	NULL
Fonds	NULL
de	NULL
la	NULL
Recherche	NULL
en	NULL
Santé	NULL
du	NULL
Québec	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
either	NULL
au-thor	NULL
:	NULL
Centre	NULL
de	NULL
Recherche	NULL
en	NULL
Infectiologie	NULL
,	NULL
RC-709	NULL
,	NULL
Centre	NULL
Hospitalier	NULL
Universitaire	NULL
de	NULL
Québec	NULL
,	NULL
Pavillon	NULL
CHUL	NULL
,	NULL
2705	NULL
boul	NULL
.	NULL

Laurier	NULL
,	NULL
Ste-Foy	NULL
,	NULL
Québec	NULL
GLIV	NULL
4G2	NULL
,	NULL
Canada	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
418-654-2705	NULL
;	NULL
Fax	NULL
:	NULL
418-654-2715	NULL
;	NULL
E-mail	NULL
:	NULL
Michel.J.Tremblay	NULL
@	NULL
erchul.ulaval.ca	NULL
or	NULL
Martin.Olivier	NULL
@	NULL
erchul	NULL
.	NULL

ulaval.ca	NULL
.	NULL

|	NULL
Burroughs	NULL
Wellcome	NULL
Fund	NULL
awardee	NULL
in	NULL
molecular	NULL
parasitology	NULL
.	NULL

27306	NULL
1	NULL
)	NULL
,	NULL
the	NULL
etiologic	NULL
agent	NULL
of	NULL
AIDS	NULL
(	NULL
1	NULL
)	NULL
,	NULL
leads	NULL
to	NULL
a	NULL
progressive	NULL
decline	NULL
of	NULL
CD4-expressing	NULL
T	NULL
cells	NULL
resulting	NULL
in	NULL
impaired	NULL
cellular	NULL
immune	NULL
functions	NULL
.	NULL

This	NULL
infection	NULL
is	NULL
influenced	NULL
by	NULL
a	NULL
complex	NULL
interplay	NULL
between	NULL
viral	NULL
and	NULL
host	NULL
factors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
microbial	NULL
agents	NULL
termed	NULL
cofactors	NULL
.	NULL

It	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
such	NULL
cofactors	NULL
may	NULL
be	NULL
important	NULL
in	NULL
disease	NULL
progression	NULL
by	NULL
enhancing	NULL
cell-to-cell	NULL
transmission	NULL
or	NULL
through	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
expression	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Mycoplasma	NULL
(	NULL
3	NULL
)	NULL
,	NULL
myco-bacteria	NULL
(	NULL
4	NULL
)	NULL
,	NULL
viruses	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
,	NULL
and	NULL
the	NULL
protozoan	NULL
parasite	NULL
Leishmania	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
may	NULL
act	NULL
as	NULL
cofactors	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV-1	NULL
infection	NULL
either	NULL
by	NULL
directly	NULL
modulating	NULL
virus	NULL
replication	NULL
or	NULL
by	NULL
inducing	NULL
a	NULL
more	NULL
profound	NULL
immunosuppressive	NULL
state	NULL
.	NULL

During	NULL
coinfections	NULL
,	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
host	NULL
to	NULL
develop	NULL
an	NULL
effective	NULL
immune	NULL
response	NULL
may	NULL
involve	NULL
the	NULL
participation	NULL
of	NULL
the	NULL
immunosuppressive	NULL
molecule	NULL
PGE	NULL
,	NULL
an	NULL
oxygenated	NULL
polyunsaturated	NULL
fatty	NULL
acid	NULL
that	NULL
contain	NULL
a	NULL
cyclopentane	NULL
ring	NULL
structure	NULL
.	NULL

PGE	NULL
,	NULL
are	NULL
molecules	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
modulate	NULL
the	NULL
immune	NULL
response	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Macro-phages	NULL
,	NULL
follicular	NULL
dendritic	NULL
cells	NULL
,	NULL
fibroblasts	NULL
,	NULL
and	NULL
vascular	NULL
en-dothelial	NULL
cells	NULL
synthesize	NULL
PGE	NULL
,	NULL
,	NULL
while	NULL
lymphocytes	NULL
do	NULL
not	NULL
secrete	NULL
this	NULL
major	NULL
product	NULL
of	NULL
arachidonic	NULL
acid	NULL
metabolism	NULL
(	NULL
11-14	NULL
)	NULL
.	NULL

A	NULL
marked	NULL
increase	NULL
in	NULL
PGE	NULL
,	NULL
production	NULL
is	NULL
generated	NULL
in	NULL
response	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
immunological	NULL
stimuli	NULL
including	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-1	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
(	NULL
TNF-a	NULL
@	NULL
)	NULL
,	NULL
antigen-anti-body	NULL
complexes	NULL
,	NULL
and	NULL
lipopolysaccharide	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
production	NULL
of	NULL
PGE	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
infection	NULL
with	NULL
several	NULL
pathogens	NULL
such	NULL
as	NULL
Leishmania	NULL
donovani	NULL
(	NULL
16	NULL
)	NULL
,	NULL
Leishmania	NULL
major	NULL
(	NULL
17	NULL
)	NULL
,	NULL
Entamoeba	NULL
histolytica	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
,	NULL
Pseudomonas	NULL
aeruginosa	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
,	NULL
Staphylococcus	NULL
epidermidis	NULL
(	NULL
22	NULL
)	NULL
,	NULL
Mycobac-terium	NULL
avium	NULL
(	NULL
28	NULL
)	NULL
,	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
24	NULL
)	NULL
,	NULL
coxsackie	NULL
virus	NULL
(	NULL
25	NULL
)	NULL
,	NULL
respiratory	NULL
syncytial	NULL
virus	NULL
(	NULL
26	NULL
)	NULL
,	NULL
and	NULL
HIV-1	NULL
(	NULL
27-30	NULL
)	NULL
.	NULL

PGE	NULL
,	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
decreasing	NULL
T-cell	NULL
proliferation	NULL
,	NULL
IL-2	NULL
production	NULL
,	NULL
and	NULL
IL-2	NULL
receptor	NULL
expression	NULL
(	NULL
15	NULL
,	NULL
31-35	NULL
)	NULL
.	NULL

PGE	NULL
,	NULL
shifts	NULL
the	NULL
balance	NULL
of	NULL
the	NULL
cellular	NULL
immune	NULL
response	NULL
away	NULL
from	NULL
T-helper	NULL
type	NULL
1	NULL
(	NULL
Thl	NULL
)	NULL
favoring	NULL
a	NULL
Th2	NULL
response	NULL
which	NULL
drives	NULL
humoral	NULL
responses	NULL
toward	NULL
the	NULL
production	NULL
of	NULL
IgE	NULL
(	NULL
36	NULL
)	NULL
.	NULL

However	NULL
,	NULL
more	NULL
recent	NULL
findings	NULL
have	NULL
depicted	NULL
PGE	NULL
as	NULL
a	NULL
pleiotropic	NULL
molecule	NULL
that	NULL
can	NULL
act	NULL
both	NULL
negatively	NULL
or	NULL
positively	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
15	NULL
)	NULL
.	NULL

An	NULL
overproduction	NULL
of	NULL
PGE	NULL
,	NULL
(	NULL
as	NULL
high	NULL
as	NULL
10	NULL
~*	NULL
M	NULL
)	NULL
is	NULL
seen	NULL
in	NULL
a	NULL
number	NULL
of	NULL
disorders	NULL
(	NULL
e.g	NULL
.	NULL

allergy	NULL
,	NULL
hyper-IgE	NULL
syndrome	NULL
,	NULL
Hodgkin	NULL
lymphoma	NULL
,	NULL
trauma	NULL
,	NULL
sepsis	NULL
,	NULL
and	NULL
transplantation	NULL
)	NULL
,	NULL
most	NULL
of	NULL
which	NULL
are	NULL
characterized	NULL
by	NULL
elevated	NULL
Th2	NULL
and	NULL
IgE	NULL
re	NULL
'*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
HIV-1	NULL
,	NULL
human	NULL
immunodeficiency	NULL
vi-rus-1	NULL
;	NULL
PGE	NULL
,	NULL
,	NULL
prostaglandin	NULL
E	NULL
,	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
TNF-a	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
;	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
;	NULL
IBMX	NULL
,	NULL
isobutylmethylxanthine	NULL
;	NULL
BAPTA	NULL
,	NULL
1,2-bis	NULL
(	NULL
O-aminophenoxy	NULL
)	NULL
ethane-N	NULL
,	NULL
N	NULL
,	NULL
N	NULL
'	NULL
,	NULL
NV	NULL
'	NULL
-tetraacetic	NULL
acid	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
Tricine	NULL
,	NULL
N-	NULL
[	NULL
2-hydroxy-1	NULL
,	NULL
l-bis	NULL
(	NULL
hy-droxymethyl	NULL
)	NULL
ethyllglycine	NULL
;	NULL
PKA	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
;	NULL
CAI	NULL
,	NULL
carboxy-amidotriazole	NULL
;	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
sponses	NULL
(	NULL
15	NULL
,	NULL
36-38	NULL
)	NULL
.	NULL

As	NULL
specified	NULL
above	NULL
,	NULL
elevated	NULL
levels	NULL
of	NULL
PGE	NULL
,	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
in	NULL
individuals	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
27-30	NULL
)	NULL
and	NULL
it	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
this	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
immunosuppressive	NULL
state	NULL
seen	NULL
in	NULL
such	NULL
virally-infected	NULL
patients	NULL
(	NULL
89	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
responsible	NULL
for	NULL
the	NULL
enhanced	NULL
prostaglandin	NULL
formation	NULL
is	NULL
still	NULL
undefined	NULL
.	NULL

The	NULL
initial	NULL
contact	NULL
between	NULL
the	NULL
virus	NULL
particle	NULL
and	NULL
its	NULL
target	NULL
cell	NULL
might	NULL
represent	NULL
the	NULL
crucial	NULL
step	NULL
leading	NULL
to	NULL
the	NULL
production	NULL
of	NULL
PGE	NULL
,	NULL
by	NULL
macrophages	NULL
.	NULL

This	NULL
concept	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
a	NULL
significant	NULL
production	NULL
of	NULL
endogenous	NULL
PGE	NULL
,	NULL
is	NULL
induced	NULL
(	NULL
20-	NULL
to	NULL
40-fold	NULL
increase	NULL
)	NULL
following	NULL
incubation	NULL
of	NULL
primary	NULL
human	NULL
monocytes	NULL
with	NULL
the	NULL
HIV-1	NULL
external	NULL
envelope	NULL
glycoprotein	NULL
gp120	NULL
(	NULL
40	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
sharp	NULL
contrast	NULL
with	NULL
this	NULL
report	NULL
,	NULL
a	NULL
previous	NULL
study	NULL
has	NULL
demonstrated	NULL
that	NULL
interaction	NULL
between	NULL
gp120	NULL
and	NULL
THP-1	NULL
,	NULL
a	NULL
human	NULL
monocytoid	NULL
cell	NULL
line	NULL
,	NULL
does	NULL
not	NULL
increase	NULL
exogenous	NULL
production	NULL
of	NULL
PGE	NULL
,	NULL
(	NULL
39	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
specify	NULL
that	NULL
,	NULL
unlike	NULL
monocyte/macrophages	NULL
,	NULL
promonocytoid	NULL
THP-1	NULL
cells	NULL
are	NULL
not	NULL
at	NULL
a	NULL
terminal	NULL
stage	NULL
of	NULL
differentiation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
monomer	NULL
form	NULL
of	NULL
gp120	NULL
was	NULL
used	NULL
in	NULL
this	NULL
study	NULL
which	NULL
might	NULL
not	NULL
parallel	NULL
physiological	NULL
conditions	NULL
where	NULL
gp120	NULL
is	NULL
under	NULL
a	NULL
multimeric	NULL
form	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
,	NULL
binding	NULL
of	NULL
PGE	NULL
,	NULL
to	NULL
one	NULL
of	NULL
its	NULL
six	NULL
different	NULL
described	NULL
receptors	NULL
(	NULL
EP	NULL
;	NULL
,	NULL
EP	NULL
;	NULL
,	NULL
EP3p	NULL
EP	NULL
3p	NULL
EPs	NULL
,	NULL
and	NULL
EP	NULL
,	NULL
)	NULL
can	NULL
lead	NULL
to	NULL
activation	NULL
of	NULL
phospholipase	NULL
C	NULL
,	NULL
phosphatidylinositol	NULL
turnover	NULL
,	NULL
activation	NULL
of	NULL
adenylate	NULL
cyclase	NULL
via	NULL
cholera	NULL
toxin-sensitive	NULL
Gg	NULL
proteins	NULL
and	NULL
mobilization	NULL
of	NULL
intracellular	NULL
Ca**	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Given	NULL
that	NULL
HIV-1	NULL
is	NULL
highly	NULL
dependent	NULL
on	NULL
intracellular	NULL
signaling	NULL
machinery	NULL
for	NULL
its	NULL
life	NULL
cycle	NULL
,	NULL
it	NULL
is	NULL
therefore	NULL
possible	NULL
that	NULL
interaction	NULL
of	NULL
PGE	NULL
,	NULL
with	NULL
its	NULL
surface	NULL
receptor	NULL
(	NULL
s	NULL
)	NULL
can	NULL
modulate	NULL
virus	NULL
replication	NULL
.	NULL

A	NULL
previous	NULL
cellular	NULL
study	NULL
supports	NULL
this	NULL
postulate	NULL
since	NULL
PGE	NULL
,	NULL
was	NULL
found	NULL
to	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
in	NULL
acutely	NULL
infected	NULL
T	NULL
lymphoid	NULL
cells	NULL
(	NULL
43	NULL
)	NULL
.	NULL

The	NULL
primary	NULL
goal	NULL
of	NULL
the	NULL
present	NULL
work	NULL
was	NULL
thus	NULL
to	NULL
investigate	NULL
the	NULL
putative	NULL
modulatory	NULL
role	NULL
of	NULL
PGE	NULL
,	NULL
on	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
(	NULL
LTR	NULL
)	NULL
at	NULL
both	NULL
biochemical	NULL
and	NULL
molecular	NULL
levels	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
we	NULL
treated	NULL
human	NULL
T	NULL
lymphoid	NULL
cells	NULL
stably	NULL
and	NULL
transiently	NULL
transfected	NULL
with	NULL
different	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
reporter	NULL
gene	NULL
vectors	NULL
with	NULL
concentrations	NULL
of	NULL
PGE	NULL
,	NULL
known	NULL
to	NULL
be	NULL
found	NULL
under	NULL
physiological	NULL
conditions	NULL
.	NULL

We	NULL
then	NULL
explored	NULL
the	NULL
intracellular	NULL
second	NULL
messengers	NULL
participating	NULL
in	NULL
PGE	NULL
,	NULL
-mediated	NULL
signaling	NULL
transduction	NULL
pathway	NULL
(	NULL
s	NULL
)	NULL
and	NULL
investigated	NULL
DNA-binding	NULL
transcriptional	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
and	NULL
cell	NULL
surface	NULL
receptor	NULL
(	NULL
s	NULL
)	NULL
implicated	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-dependent	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Reagents-PGE	NULL
,	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
phytohe-magglutinin	NULL
(	NULL
PHA	NULL
)	NULL
,	NULL
indomethacin	NULL
and	NULL
dibutyryl-cAMP	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

H7	NULL
was	NULL
purchased	NULL
from	NULL
Seikagaku	NULL
America	NULL
Inc.	NULL
(	NULL
Tampa	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

BAPTA/AM	NULL
,	NULL
IBMX	NULL
,	NULL
MDL-12,830A	NULL
,	NULL
and	NULL
HA-1004	NULL
were	NULL
purchased	NULL
from	NULL
BioMol	NULL
(	NULL
Plymouth	NULL
Meeting	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

The	NULL
calcium	NULL
inhibitor	NULL
CAI	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
E.	NULL
C.	NULL
Kohn	NULL
(	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

AH	NULL
23848B	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
S.	NULL
G.	NULL
Lister	NULL
(	NULL
Glaxo	NULL
Wellcome	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
.	NULL

Trizol	NULL
came	NULL
from	NULL
Life	NULL
Technolo-gies	NULL
,	NULL
Inc.	NULL
(	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
PGE	NULL
,	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
were	NULL
prepared	NULL
by	NULL
dissolving	NULL
the	NULL
lyophilized	NULL
product	NULL
into	NULL
absolute	NULL
ethanol	NULL
and	NULL
were	NULL
stored	NULL
at	NULL
-20	NULL
°C	NULL
until	NULL
needed	NULL
.	NULL

Cells	NULL
and	NULL
Culture	NULL
Conditions-The	NULL
parental	NULL
lymphoid	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
Jurkat	NULL
E6.1	NULL
,	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
ATCC	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
while	NULL
1G5	NULL
was	NULL
supplied	NULL
by	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
,	NULL
Division	NULL
of	NULL
AIDS	NULL
,	NULL
NIAID	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Health	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

1G5	NULL
is	NULL
a	NULL
clonal	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
which	NULL
has	NULL
been	NULL
stably	NULL
transfected	NULL
with	NULL
a	NULL
luciferase	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Hyclone	NULL
Laboratories	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
0.22	NULL
%	NULL
NaHCO	NULL
,	NULL
and	NULL
were	NULL
maintained	NULL
at	NULL
37	NULL
°C	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
humidified	NULL
atmosphere	NULL
.	NULL

Plasmids	NULL
and	NULL
Antibodies-In	NULL
our	NULL
studies	NULL
,	NULL
we	NULL
have	NULL
used	NULL
pLTR-LUC	NULL
and	NULL
that	NULL
have	NULL
been	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
K.	NULL
Calame	NULL
(	NULL
Columbia	NULL
University	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

These	NULL
molecular	NULL
constructs	NULL
contain	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
wild-type	NULL
(	NULL
GGGACTTTCC	NULL
)	NULL
27307	NULL
or	NULL
NF-	NULL
«	NULL
B-mutated	NULL
(	NULL
CTCACTTTCC	NULL
)	NULL
HIV-lp	NULL
;	NULL
,	NULL
,	NULL
LTR	NULL
(	NULL
-458	NULL
to	NULL
+80	NULL
)	NULL
(	NULL
45	NULL
)	NULL
.	NULL

We	NULL
have	NULL
also	NULL
used	NULL
the	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
vector	NULL
which	NULL
contains	NULL
the	NULL
minimal	NULL
HIV-1	NULL
«	NULL
B	NULL
region	NULL
and	NULL
a	NULL
TATA	NULL
box	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
46	NULL
)	NULL
.	NULL

This	NULL
plasmid	NULL
is	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
W.	NULL
C.	NULL
Greene	NULL
(	NULL
The	NULL
J.	NULL
Gladstone	NULL
Institutes	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
construct	NULL
pNF-	NULL
«	NULL
xB-LUC	NULL
contains	NULL
five	NULL
(	NULL
5	NULL
)	NULL
consensus	NULL
sequences	NULL
of	NULL
NF-B-binding	NULL
sites	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

NFAT-LUC	NULL
contains	NULL
the	NULL
IL-2	NULL
minimal	NULL
promoter	NULL
with	NULL
three	NULL
tandem	NULL
copies	NULL
of	NULL
NFAT-binding	NULL
site	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analyses	NULL
were	NULL
performed	NULL
using	NULL
human	NULL
EP	NULL
,	NULL
,	NULL
EP	NULL
,	NULL
,	NULL
EP	NULL
,	NULL
,	NULL
and	NULL
EP	NULL
,	NULL
subtypes	NULL
cDNA	NULL
frag-ments	NULL
.	NULL

The	NULL
cDNAs	NULL
for	NULL
human	NULL
prostanoid	NULL
receptor	NULL
EP	NULL
,	NULL
(	NULL
1.3	NULL
kilobases	NULL
)	NULL
,	NULL
EP	NULL
,	NULL
(	NULL
1.8	NULL
kilobases	NULL
)	NULL
,	NULL
and	NULL
EP	NULL
,	NULL
(	NULL
1.5	NULL
kilobases	NULL
)	NULL
were	NULL
kind	NULL
gifts	NULL
from	NULL
Dr.	NULL
M.	NULL
Abramovitz	NULL
(	NULL
Merck	NULL
Frost	NULL
,	NULL
Qué	NULL
,	NULL
Canada	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
for	NULL
hEP	NULL
,	NULL
(	NULL
1.1	NULL
kilobases	NULL
)	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
Dr.	NULL
K.	NULL
M.	NULL
Kedzie	NULL
(	NULL
Allergan	NULL
,	NULL
Irvine	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
polyclonal	NULL
antibody	NULL
specific	NULL
for	NULL
EP	NULL
,	NULL
was	NULL
obtained	NULL
from	NULL
Cayman	NULL
Chemical	NULL
(	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
.	NULL

This	NULL
rabbit	NULL
serum	NULL
is	NULL
directed	NULL
against	NULL
a	NULL
synthetic	NULL
peptide	NULL
from	NULL
the	NULL
human	NULL
EP	NULL
,	NULL
receptor	NULL
.	NULL

Modulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
-In	NULL
order	NULL
to	NULL
assess	NULL
whether	NULL
PGE	NULL
,	NULL
could	NULL
modulate	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
,	NULL
1G5	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
PHA	NULL
(	NULL
8	NULL
ug/ml	NULL
)	NULL
,	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
clone	NULL
OKT3	NULL
at	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml1	NULL
)	NULL
,	NULL
and	NULL
TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
:	NULL
R	NULL
&	NULL
D	NULL
systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Next	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Dose-response	NULL
experiments	NULL
were	NULL
done	NULL
using	NULL
a	NULL
similar	NULL
number	NULL
of	NULL
cells	NULL
,	NULL
washed	NULL
once	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
fresh	NULL
complete	NULL
culture	NULL
medium	NULL
before	NULL
incubation	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
PGE	NULL
,	NULL
at	NULL
final	NULL
concentrations	NULL
of	NULL
1	NULL
,	NULL
10	NULL
,	NULL
100	NULL
,	NULL
and	NULL
1000	NULL
nM	NULL
.	NULL

Kinetic	NULL
experiments	NULL
were	NULL
done	NULL
by	NULL
incubating	NULL
1G5	NULL
cells	NULL
with	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
for	NULL
2	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
24	NULL
h.	NULL
In	NULL
some	NULL
experiments	NULL
,	NULL
1G5	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
second	NULL
messenger	NULL
inhibitors	NULL
such	NULL
as	NULL
H7	NULL
,	NULL
HA-1004	NULL
,	NULL
BAPTA/AM	NULL
,	NULL
indomethacin	NULL
,	NULL
MDL-12,330A	NULL
,	NULL
and	NULL
IBMX	NULL
at	NULL
subcytotoxic	NULL
and	NULL
subcytostatic	NULL
concentrations	NULL
prior	NULL
to	NULL
treatment	NULL
with	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
for	NULL
8	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
inhibitor	NULL
CAI	NULL
requires	NULL
a	NULL
pretreatment	NULL
of	NULL
at	NULL
least	NULL
8	NULL
h	NULL
for	NULL
optimum	NULL
inhibition	NULL
and	NULL
shows	NULL
no	NULL
acute	NULL
interference	NULL
with	NULL
the	NULL
growth	NULL
properties	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
47	NULL
)	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
performed	NULL
three	NULL
times	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
evaluated	NULL
for	NULL
each	NULL
quadruplicate	NULL
samples	NULL
by	NULL
a	NULL
modified	NULL
version	NULL
of	NULL
a	NULL
previously	NULL
published	NULL
procedure	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
following	NULL
the	NULL
incubation	NULL
period	NULL
,	NULL
100	NULL
ul	NULL
of	NULL
cell-free	NULL
supernatant	NULL
were	NULL
withdrawn	NULL
from	NULL
each	NULL
well	NULL
and	NULL
25	NULL
ul	NULL
of	NULL
cell	NULL
culture	NULL
lysis	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Tris	NULL
phosphate	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
2	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
)	NULL
were	NULL
added	NULL
before	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
cell	NULL
extract	NULL
(	NULL
20	NULL
pl	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
100	NULL
ul	NULL
of	NULL
luciferase	NULL
assay	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tricine	NULL
,	NULL
1.07	NULL
mM	NULL
(	NULL
MgCO	NULL
,	NULL
)	NULL
,	NULL
Mg	NULL
(	NULL
OH	NULL
)	NULL
y5H,0	NULL
,	NULL
2.67	NULL
mM	NULL
MgSO	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
270	NULL
um	NULL
coenzyme	NULL
A	NULL
,	NULL
470	NULL
uM	NULL
luciferin	NULL
,	NULL
580	NULL
uM	NULL
ATP	NULL
,	NULL
and	NULL
33.3	NULL
mM	NULL
dithiothreitol	NULL
)	NULL
and	NULL
the	NULL
sample	NULL
was	NULL
read	NULL
in	NULL
the	NULL
counting	NULL
chamber	NULL
of	NULL
a	NULL
standard	NULL
liquid	NULL
scintillation	NULL
counter	NULL
equipped	NULL
with	NULL
a	NULL
single-photon	NULL
monitor	NULL
software	NULL
(	NULL
Beckman	NULL
Instruments	NULL
,	NULL
Fuller-ton	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Total	NULL
photo-events	NULL
were	NULL
measured	NULL
over	NULL
a	NULL
30-s	NULL
time	NULL
lapse	NULL
.	NULL

Transient	NULL
Transfection	NULL
by	NULL
DEAE-dextran-Jurkat	NULL
E6.1	NULL
(	NULL
5	NULL
to	NULL
10	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
first	NULL
washed	NULL
once	NULL
in	NULL
a	NULL
TS	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
5	NULL
mM	NULL
KCl	NULL
,	NULL
0.6	NULL
mM	NULL
NaHPO	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
0.7	NULL
mM	NULL
CaCl	NULL
,	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
0.5-1	NULL
ml	NULL
of	NULL
TS	NULL
containing	NULL
10-20	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
plasmids	NULL
and	NULL
500	NULL
ug/ml	NULL
DEAE-dextran	NULL
(	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

The	NULL
cells/	NULL
TS/plasmid/DEAE-dextran	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
25	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Thereafter	NULL
,	NULL
cells	NULL
were	NULL
diluted	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10°	NULL
per	NULL
ml	NULL
using	NULL
complete	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
100	NULL
uM	NULL
chloroquine	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

After	NULL
45	NULL
min	NULL
of	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
cells	NULL
were	NULL
centrifuged	NULL
,	NULL
washed	NULL
once	NULL
,	NULL
resuspended	NULL
in	NULL
complete	NULL
culture	NULL
medium	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
24	NULL
h.	NULL
To	NULL
minimize	NULL
variations	NULL
in	NULL
plasmid	NULL
transfection	NULL
efficiencies	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
pooled	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
and	NULL
were	NULL
next	NULL
separated	NULL
into	NULL
various	NULL
treatment	NULL
groups	NULL
as	NULL
follow	NULL
.	NULL

Transiently	NULL
transfected	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
a	NULL
density	NULL
of	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
(	NULL
100	NULL
ul	NULL
)	NULL
in	NULL
96-well	NULL
flat-bottom	NULL
plates	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
,	NULL
PHA/PMA	NULL
(	NULL
8	NULL
ug/ml	NULL
and	NULL
20	NULL
ng/ml	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
and	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
for	NULL
a	NULL
period	NULL
of	NULL
8	NULL
h	NULL
at	NULL
87°C	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
assessed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay-Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
49	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
1GS	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
PGE	NULL
,	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
or	NULL
TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

The	NULL
incubation	NULL
of	NULL
cells	NULL
with	NULL
the	NULL
stimulating	NULL
agents	NULL
was	NULL
terminated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
ice-cold	NULL
PBS	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
microscale	NULL
preparation	NULL
protocol	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Sedimented	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
400	NULL
ul	NULL
of	NULL
cold	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
nM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
nM	NULL
KCl	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27308	NULL
0.2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
.	NULL

After	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
the	NULL
lysate	NULL
was	NULL
vortexed	NULL
for	NULL
10	NULL
s	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
centrifuged	NULL
for	NULL
10	NULL
s	NULL
at	NULL
12,000	NULL
x	NULL
g.	NULL
The	NULL
supernatant	NULL
fraction	NULL
was	NULL
discarded	NULL
and	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
cold	NULL
buffer	NULL
B	NULL
(	NULL
20	NULL
mm	NULL
HEPES-KOH	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
0.2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Cellular	NULL
debris	NULL
were	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
12,000	NULL
X	NULL
g	NULL
for	NULL
2	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
the	NULL
supernatant	NULL
fractions	NULL
were	NULL
stored	NULL
at	NULL
-70	NULL
°C	NULL
until	NULL
used	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
to	NULL
perform	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Protein	NULL
content	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
commercial	NULL
BCA	NULL
Protein	NULL
Assay	NULL
Reagent	NULL
(	NULL
Pierce	NULL
,	NULL
Rockfold	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
15	NULL
pl	NULL
of	NULL
buffer	NULL
of	NULL
a	NULL
binding	NULL
solution	NULL
(	NULL
100	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
40	NULL
%	NULL
glycerol	NULL
,	NULL
10	NULL
%	NULL
Ficoll	NULL
,	NULL
250	NULL
mM	NULL
KCI	NULL
,	NULL
10	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
nuclease-free	NULL
bovine	NULL
serum	NULL
albumin	NULL
fraction	NULL
V	NULL
)	NULL
containing	NULL
1	NULL
ng	NULL
of	NULL
*°P-5'-end-labeled	NULL
double-stranded	NULL
(	NULL
dsDNA	NULL
)	NULL
oligonucleotide	NULL
.	NULL

Double-stranded	NULL
DNA	NULL
(	NULL
100	NULL
ng	NULL
)	NULL
was	NULL
labeled	NULL
with	NULL
and	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
in	NULL
a	NULL
kinase	NULL
buffer	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

This	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
with	NULL
5	NULL
ul	NULL
of	NULL
0.2	NULL
M	NULL
EDTA	NULL
.	NULL

The	NULL
labeled	NULL
oligonucleotide	NULL
was	NULL
extracted	NULL
with	NULL
phenol/chloroform	NULL
and	NULL
passed	NULL
trough	NULL
a	NULL
G-50	NULL
spin	NULL
column	NULL
.	NULL

The	NULL
double-stranded	NULL
DNA	NULL
oligonu-cleotide	NULL
,	NULL
which	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
contained	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B-binding	NULL
site	NULL
corresponding	NULL
to	NULL
the	NULL
sequence	NULL
5'-ATGTGAGGGGACTTTC-CCAGGC-3	NULL
'	NULL
and	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Ca	NULL
)	NULL
.	NULL

DNANF-	NULL
«	NULL
B	NULL
complexes	NULL
were	NULL
resolved	NULL
from	NULL
free	NULL
labeled	NULL
DNA	NULL
by	NULL
electrophoresis	NULL
in	NULL
native	NULL
4	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
polyacrylamide	NULL
gel	NULL
containing	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
8.5	NULL
)	NULL
,	NULL
200	NULL
nM	NULL
glycine	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
subsequently	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

Northern	NULL
Blot	NULL
Analysis-Total	NULL
RNA	NULL
was	NULL
extracted	NULL
by	NULL
the	NULL
Trizol	NULL
method	NULL
(	NULL
51	NULL
,	NULL
52	NULL
)	NULL
from	NULL
1G5	NULL
and	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
.	NULL

Fifteen	NULL
micrograms	NULL
of	NULL
total	NULL
RNA	NULL
were	NULL
separated	NULL
on	NULL
formaldehyde-agarose	NULL
gel	NULL
(	NULL
1	NULL
%	NULL
agarose	NULL
,	NULL
1	NULL
X	NULL
formaldehyde	NULL
gel	NULL
buffer	NULL
MOPS	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
40	NULL
mM	NULL
sodium	NULL
acetate	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
2.2	NULL
M	NULL
formaldehyde	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
transferred	NULL
to	NULL
Hybond-N	NULL
nylon	NULL
membranes	NULL
(	NULL
Amersham	NULL
)	NULL
by	NULL
capillary	NULL
action	NULL
using	NULL
10	NULL
X	NULL
SSC	NULL
(	NULL
8	NULL
M	NULL
NaCl	NULL
,	NULL
0.3	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
fixed	NULL
to	NULL
the	NULL
membrane	NULL
by	NULL
UV	NULL
exposure	NULL
and	NULL
hybridized	NULL
with	NULL
radiolabeled	NULL
probes	NULL
for	NULL
the	NULL
EP	NULL
receptors	NULL
(	NULL
EP	NULL
,	NULL
,	NULL
EP	NULL
,	NULL
,	NULL
EP	NULL
,	NULL
,	NULL
and	NULL
EP	NULL
,	NULL
)	NULL
at	NULL
42	NULL
°C	NULL
in	NULL
50	NULL
%	NULL
formamide	NULL
,	NULL
5	NULL
X	NULL
SSPE	NULL
,	NULL
5	NULL
X	NULL
Denhardt	NULL
's	NULL
solution	NULL
,	NULL
0.5	NULL
%	NULL
SDS	NULL
,	NULL
100	NULL
ug/ml	NULL
denatured	NULL
fragmented	NULL
salmon	NULL
sperm	NULL
DNA	NULL
.	NULL

Blots	NULL
were	NULL
washed	NULL
and	NULL
autoradiographed	NULL
at	NULL
-70	NULL
°C	NULL
.	NULL

Flow	NULL
Cytometry-Cell	NULL
surface	NULL
expression	NULL
of	NULL
hEP	NULL
,	NULL
receptor	NULL
was	NULL
evaluated	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
follow	NULL
.	NULL

Cell	NULL
lines	NULL
1G5	NULL
and	NULL
Jurkat	NULL
66.1	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
containing	NULL
2	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
PBS	NULL
pH	NULL
7.4	NULL
+	NULL
2	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
PBSA	NULL
)	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
PBSA	NULL
to	NULL
which	NULL
was	NULL
added	NULL
0.5	NULL
ug	NULL
of	NULL
polyclonal	NULL
rabbit	NULL
anti-hEP	NULL
,	NULL
antibody	NULL
,	NULL
vortexed	NULL
gently	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
80	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Cells	NULL
were	NULL
subsequently	NULL
washed	NULL
with	NULL
PBSA	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
pul	NULL
of	NULL
PBSA	NULL
containing	NULL
fluorescein	NULL
isothiocyanate-labeled	NULL
chicken	NULL
anti-rabbit	NULL
IgG	NULL
antibody	NULL
(	NULL
0.5	NULL
ug	NULL
total	NULL
)	NULL
and	NULL
further	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Cells	NULL
were	NULL
finally	NULL
centrifuged	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
%	NULL
paraformal-dehyde	NULL
in	NULL
PBS	NULL
before	NULL
being	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
EPICS	NULL
XL	NULL
,	NULL
Coulter	NULL
Corp.	NULL
,	NULL
Miami	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Experiments	NULL
with	NULL
the	NULL
EP	NULL
,	NULL
Receptor-specific	NULL
Antagonist	NULL
AH	NULL
23848B-Assays	NULL
with	NULL
AH	NULL
28848B	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
1G5	NULL
cells	NULL
with	NULL
30	NULL
um	NULL
AH	NULL
23848B	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
(	NULL
58	NULL
)	NULL
.	NULL

After	NULL
this	NULL
pretreatment	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
for	NULL
8	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
three	NULL
times	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
monitored	NULL
as	NULL
described	NULL
above	NULL
.	NULL

RESULTS	NULL
Modulation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
Gene	NULL
Expression	NULL
in	NULL
T	NULL
Cells	NULL
by	NULL
PGE	NULL
,	NULL
-In	NULL
order	NULL
to	NULL
assess	NULL
whether	NULL
PGE	NULL
,	NULL
could	NULL
affect	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
,	NULL
we	NULL
initially	NULL
set	NULL
out	NULL
a	NULL
dose-response	NULL
experiment	NULL
which	NULL
was	NULL
performed	NULL
with	NULL
PGE	NULL
in	NULL
a	NULL
24-h	NULL
incubation	NULL
period	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
a	NULL
steady	NULL
increase	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
in	NULL
1G5	NULL
cells	NULL
starting	NULL
at	NULL
as	NULL
little	NULL
as	NULL
1	NULL
nm	NULL
concentration	NULL
of	NULL
PGE	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
PGE	NULL
,	NULL
was	NULL
reconstituted	NULL
in	NULL
absolute	NULL
ethanol	NULL
to	NULL
get	NULL
a	NULL
stock	NULL
solution	NULL
of	NULL
1	NULL
mm	NULL
which	NULL
was	NULL
serially	NULL
diluted	NULL
in	NULL
complete	NULL
culture	NULL
medium	NULL
to	NULL
get	NULL
our	NULL
working	NULL
dilutions	NULL
(	NULL
1	NULL
,	NULL
10	NULL
,	NULL
100	NULL
,	NULL
and	NULL
1000	NULL
nx	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
1GS5	NULL
cells	NULL
with	NULL
the	NULL
concentration	NULL
of	NULL
ethanol	NULL
corresponding	NULL
to	NULL
the	NULL
one	NULL
used	NULL
with	NULL
1000	NULL
nm	NULL
PGE	NULL
,	NULL
resulted	NULL
in	NULL
a	NULL
1.5-fold	NULL
increase	NULL
of	NULL
HIV-1	NULL
LTR	NULL
dependent	NULL
activity	NULL
,	NULL
while	NULL
no	NULL
effect	NULL
was	NULL
seen	NULL
with	NULL
the	NULL
equivalent	NULL
ethanol	NULL
concentration	NULL
for	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
(	NULL
data	NULL
not	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
A	NULL
10	NULL
7.5	NULL
7	NULL
J	NULL
.	NULL

3	NULL
3	NULL
7	NULL
£00	NULL
57	NULL
T.	NULL
3	NULL
I	NULL
C	NULL
E	NULL
2.5	NULL
0	NULL
I	NULL
I	NULL
I	NULL
I	NULL
PGEq	NULL
(	NULL
nM	NULL
)	NULL
:	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
us	NULL
100	NULL
<	NULL
=	NULL
To	NULL
ts	NULL
{	NULL
-§	NULL
B	NULL
3	NULL
&	NULL
504	NULL
E	NULL
E	NULL
#	NULL
25	NULL
€	NULL
9	NULL
3	NULL
(	NULL
=	NULL
]	NULL
0	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
00	NULL
4008	NULL
12	NULL
160	NULL
200	NULL
240	NULL
28	NULL
Time	NULL
post-treatment	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Dose-dependent	NULL
and	NULL
kinetic	NULL
analyses	NULL
of	NULL
PGE	NULL
,	NULL
-mediated	NULL
positive	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
1G5	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
increasing	NULL
doses	NULL
of	NULL
PGE	NULL
,	NULL
(	NULL
1	NULL
,	NULL
10	NULL
,	NULL
100	NULL
,	NULL
and	NULL
1000	NULL
nM	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
evaluated	NULL
for	NULL
luciferase	NULL
activity	NULL
by	NULL
scintillation	NULL
count	NULL
.	NULL

B	NULL
,	NULL
1G5	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
(	NULL
0	NULL
)	NULL
or	NULL
were	NULL
stimulated	NULL
with	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
(	NULL
®	NULL
)	NULL
for	NULL
different	NULL
time	NULL
periods	NULL
(	NULL
2	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
24	NULL
h	NULL
)	NULL
prior	NULL
to	NULL
monitoring	NULL
luciferase	NULL
activity	NULL
in	NULL
cell	NULL
lysates	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
(	NULL
+8.D	NULL
.	NULL
)	NULL

of	NULL
four	NULL
determinations	NULL
and	NULL
are	NULL
expressed	NULL
in	NULL
panel	NULL
!	NULL

A	NULL
as	NULL
fold	NULL
induction	NULL
relative	NULL
to	NULL
basal	NULL
luciferase	NULL
activity	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
considered	NULL
as	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
subsequent	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
100	NULL
nm	NULL
PGE	NULL
,	NULL
to	NULL
avoid	NULL
any	NULL
putative	NULL
influence	NULL
of	NULL
ethanol	NULL
on	NULL
PGE	NULL
,	NULL
-mediated	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
.	NULL

Kinetics	NULL
analyses	NULL
were	NULL
next	NULL
performed	NULL
to	NULL
determine	NULL
the	NULL
optimal	NULL
incubation	NULL
time	NULL
for	NULL
this	NULL
PGE	NULL
,	NULL
-mediated	NULL
HIV-1	NULL
LTR-driven	NULL
activation	NULL
.	NULL

The	NULL
maximal	NULL
positive	NULL
effect	NULL
of	NULL
PGE	NULL
,	NULL
was	NULL
seen	NULL
8	NULL
h	NULL
after	NULL
the	NULL
initiation	NULL
of	NULL
treatment	NULL
(	NULL
fold	NULL
enhancement	NULL
of	NULL
7.4	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Although	NULL
this	NULL
type	NULL
of	NULL
kinetic	NULL
might	NULL
be	NULL
reminiscent	NULL
of	NULL
degradation	NULL
of	NULL
PGE	NULL
,	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
since	NULL
similar	NULL
kinetic	NULL
of	NULL
time-depend-ent	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
were	NULL
measured	NULL
with	NULL
activators	NULL
such	NULL
as	NULL
TNF-a	NULL
,	NULL
PHA	NULL
,	NULL
and	NULL
PMA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
preincubation	NULL
of	NULL
PGE	NULL
,	NULL
in	NULL
complete	NULL
culture	NULL
medium	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
resulted	NULL
in	NULL
equal	NULL
fold-induction	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
in	NULL
1G5	NULL
cells	NULL
as	NULL
compared	NULL
with	NULL
incubation	NULL
with	NULL
fresh	NULL
PGE	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
demonstrates	NULL
that	NULL
PGE	NULL
,	NULL
is	NULL
fairly	NULL
stable	NULL
under	NULL
these	NULL
experimental	NULL
conditions	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
activation	NULL
of	NULL
HIV-1	NULL
regulatory	NULL
elements	NULL
by	NULL
PGE	NULL
,	NULL
was	NULL
rapid	NULL
and	NULL
transient	NULL
,	NULL
thereby	NULL
suggesting	NULL
that	NULL
the	NULL
effect	NULL
was	NULL
direct	NULL
and	NULL
was	NULL
resulting	NULL
from	NULL
PGE	NULL
,	NULL
-mediated	NULL
signal	NULL
transduction	NULL
events	NULL
.	NULL

Given	NULL
that	NULL
PGE	NULL
,	NULL
is	NULL
generally	NULL
seen	NULL
as	NULL
a	NULL
down-modulator	NULL
of	NULL
T-cell	NULL
activation	NULL
,	NULL
we	NULL
were	NULL
next	NULL
interested	NULL
in	NULL
determining	NULL
the	NULL
action	NULL
of	NULL
PGE	NULL
,	NULL
on	NULL
typical	NULL
pathways	NULL
known	NULL
to	NULL
lead	NULL
to	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

1G5	NULL
cells	NULL
were	NULL
hence	NULL
stimulated	NULL
with	NULL
various	NULL
HIV-1	NULL
LTR	NULL
activators	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
PGE	NULL
,	NULL
for	NULL
8	NULL
h.	NULL
These	NULL
stimuli	NULL
were	NULL
shown	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
to	NULL
act	NULL
as	NULL
potent	NULL
inducers	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
(	NULL
fold	NULL
increase	NULL
over	NULL
un-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
Luciferase	NULL
activity	NULL
(	NULL
cpm	NULL
x	NULL
106	NULL
)	NULL
T	NULL
<	NULL
ad	NULL
<	NULL
5	NULL
Treatment	NULL
:	NULL
%	NULL
E	NULL
h	NULL
E	NULL
g	NULL
C	NULL
©	NULL
&	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Activation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
by	NULL
several	NULL
stimuli	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
PGE	NULL
,	NULL
.	NULL

1G5	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PHA	NULL
(	NULL
3	NULL
pg/ml	NULL
)	NULL
,	NULL
OKT3	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
or	NULL
TNF-	NULL
@	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
0	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
®	NULL
)	NULL
of	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
for	NULL
8	NULL
h.	NULL
Cell	NULL
lysates	NULL
were	NULL
evaluated	NULL
for	NULL
luciferase	NULL
activity	NULL
by	NULL
scintillation	NULL
count	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
(	NULL
+	NULL
S.D	NULL
.	NULL
)	NULL

of	NULL
four	NULL
determinations	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

treated	NULL
1G5	NULL
cells	NULL
:	NULL
PHA	NULL
,	NULL
20.8	NULL
:	NULL
OKT3	NULL
,	NULL
16.8	NULL
;	NULL
PMA	NULL
,	NULL
76.4	NULL
;	NULL
and	NULL
TNF	NULL
-a	NULL
«	NULL
,	NULL
17.7	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
a	NULL
marked	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR-dependent	NULL
luciferase	NULL
activity	NULL
was	NULL
also	NULL
seen	NULL
when	NULL
1G5	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
PGE	NULL
,	NULL
alone	NULL
(	NULL
10.9-fold	NULL
increase	NULL
over	NULL
untreated	NULL
1G5	NULL
cells	NULL
)	NULL
.	NULL

A	NULL
PGE	NULL
,	NULL
-mediated	NULL
activating	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR	NULL
was	NULL
also	NULL
present	NULL
with	NULL
all	NULL
stimuli	NULL
used	NULL
in	NULL
this	NULL
set	NULL
of	NULL
experiments	NULL
(	NULL
fold	NULL
increase	NULL
over	NULL
1G5	NULL
cells	NULL
treated	NULL
with	NULL
each	NULL
stimuli	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
PGE	NULL
:	NULL
PHA	NULL
,	NULL
1.8	NULL
;	NULL
OKT3	NULL
,	NULL
2.3	NULL
;	NULL
PMA	NULL
,	NULL
1.2	NULL
;	NULL
and	NULL
TNF-a	NULL
,	NULL
4.3	NULL
)	NULL
.	NULL

It	NULL
was	NULL
thus	NULL
apparent	NULL
that	NULL
PGE	NULL
,	NULL
specifically	NULL
synergized	NULL
with	NULL
TNF-a	NULL
in	NULL
activating	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
clearly	NULL
indicated	NULL
that	NULL
PGE	NULL
,	NULL
could	NULL
further	NULL
increase	NULL
the	NULL
overall	NULL
positive	NULL
effect	NULL
mediated	NULL
by	NULL
various	NULL
HIV-1	NULL
LTR-activat-ing	NULL
agents	NULL
and	NULL
thus	NULL
confirmed	NULL
that	NULL
PGE	NULL
,	NULL
could	NULL
be	NULL
considered	NULL
by	NULL
itself	NULL
as	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
HIV-1	NULL
LTR	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
biosynthesis	NULL
of	NULL
prostaglandins	NULL
is	NULL
known	NULL
to	NULL
be	NULL
regulated	NULL
at	NULL
two	NULL
different	NULL
levels	NULL
.	NULL

The	NULL
arachidonic	NULL
acid	NULL
,	NULL
the	NULL
precursor	NULL
form	NULL
,	NULL
is	NULL
stored	NULL
in	NULL
membrane	NULL
phospholipids	NULL
prior	NULL
to	NULL
its	NULL
release	NULL
into	NULL
cells	NULL
by	NULL
phospholipase	NULL
A	NULL
;	NULL
.	NULL

Free	NULL
arachidonic	NULL
acid	NULL
is	NULL
then	NULL
metabolized	NULL
by	NULL
cyclooxygenase	NULL
to	NULL
an	NULL
intermediate	NULL
that	NULL
leads	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
prostaglandins	NULL
(	NULL
54	NULL
)	NULL
.	NULL

To	NULL
exclude	NULL
any	NULL
effect	NULL
by	NULL
endogenous	NULL
PGE	NULL
,	NULL
in	NULL
our	NULL
studies	NULL
,	NULL
1GS	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
concentrations	NULL
of	NULL
indomethacin	NULL
sufficient	NULL
to	NULL
inhibit	NULL
cy-clooxygenase-1	NULL
(	NULL
0.4	NULL
,	NULL
0.8	NULL
,	NULL
2.0	NULL
,	NULL
and	NULL
10.0	NULL
um	NULL
)	NULL
and	NULL
cyclooxygen-ase-2	NULL
(	NULL
150	NULL
um	NULL
)	NULL
(	NULL
55	NULL
)	NULL
before	NULL
stimulation	NULL
with	NULL
PGE	NULL
,	NULL
for	NULL
8	NULL
h.	NULL
No	NULL
changes	NULL
in	NULL
PGE	NULL
,	NULL
-dependent	NULL
increase	NULL
in	NULL
HIV-LTR	NULL
driven	NULL
luciferase	NULL
activity	NULL
could	NULL
be	NULL
detected	NULL
with	NULL
indomethacin	NULL
suggesting	NULL
that	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
was	NULL
only	NULL
due	NULL
to	NULL
exogeneous	NULL
PGE	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Signaling	NULL
Events	NULL
Involved	NULL
in	NULL
PGE	NULL
,	NULL
-mediated	NULL
Enhancement	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity-Our	NULL
results	NULL
so	NULL
far	NULL
suggested	NULL
that	NULL
binding	NULL
of	NULL
PGE	NULL
,	NULL
to	NULL
its	NULL
cell	NULL
surface	NULL
receptors	NULL
(	NULL
EPs	NULL
)	NULL
triggers	NULL
signal	NULL
transduction	NULL
that	NULL
positively	NULL
affect	NULL
HIV-1	NULL
LTR	NULL
expression	NULL
.	NULL

Several	NULL
specific	NULL
inhibitors	NULL
were	NULL
used	NULL
to	NULL
identify	NULL
cellular	NULL
element	NULL
(	NULL
s	NULL
)	NULL
participating	NULL
to	NULL
the	NULL
signaling	NULL
events	NULL
involved	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-induced	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
.	NULL

1GS5	NULL
cells	NULL
were	NULL
first	NULL
pretreated	NULL
with	NULL
H7	NULL
,	NULL
a	NULL
selective	NULL
serine/threonine	NULL
kinase	NULL
inhibitor	NULL
that	NULL
can	NULL
inhibit	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
(	NULL
K	NULL
;	NULL
=	NULL
3.0	NULL
um	NULL
)	NULL
,	NULL
PKC	NULL
(	NULL
K	NULL
;	NULL
=	NULL
6.0	NULL
uM	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
PKG	NULL
(	NULL
K	NULL
;	NULL
=	NULL
5.8	NULL
um	NULL
)	NULL
(	NULL
56	NULL
)	NULL
.	NULL

A	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
PGE	NULL
,	NULL
-mediated	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
was	NULL
seen	NULL
when	NULL
1GS	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
H7	NULL
at	NULL
concentrations	NULL
sufficient	NULL
to	NULL
inhibit	NULL
all	NULL
of	NULL
these	NULL
enzymes	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

To	NULL
more	NULL
deeply	NULL
scrutinize	NULL
signaling	NULL
molecule	NULL
(	NULL
s	NULL
)	NULL
implicated	NULL
in	NULL
PGE	NULL
,	NULL
-induced	NULL
positive	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
,	NULL
cells	NULL
were	NULL
27309	NULL
next	NULL
pretreated	NULL
with	NULL
HA-1004	NULL
,	NULL
a	NULL
serine/threonine	NULL
kinase	NULL
inhibitor	NULL
that	NULL
preferentially	NULL
inhibits	NULL
PKA	NULL
(	NULL
K	NULL
;	NULL
=	NULL
2.3	NULL
ux	NULL
)	NULL
and	NULL
PKG	NULL
(	NULL
K	NULL
;	NULL
=	NULL
1.3	NULL
uM	NULL
)	NULL
over	NULL
PKC	NULL
(	NULL
K	NULL
;	NULL
=	NULL
40.0	NULL
um	NULL
)	NULL
(	NULL
56	NULL
)	NULL
.	NULL

The	NULL
PGE	NULL
,	NULL
-mediated	NULL
activation	NULL
of	NULL
HIV-1	NULL
transcription	NULL
was	NULL
almost	NULL
completely	NULL
abrogated	NULL
by	NULL
a	NULL
pretreatment	NULL
with	NULL
HA-1004	NULL
at	NULL
concentrations	NULL
sufficient	NULL
to	NULL
inhibit	NULL
both	NULL
PKA	NULL
and	NULL
PKG	NULL
,	NULL
but	NULL
not	NULL
PKC	NULL
(	NULL
1	NULL
and	NULL
5	NULL
pum	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

To	NULL
clearly	NULL
discriminate	NULL
between	NULL
PKA	NULL
and	NULL
PKG	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-induced	NULL
signaling	NULL
cascade	NULL
,	NULL
1G5	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
adenylate	NULL
cyclase	NULL
(	NULL
MDL-12	NULL
,	NULL
330A	NULL
)	NULL
(	NULL
57-59	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
HIV-1	NULL
LTR-mediated	NULL
reporter	NULL
gene	NULL
expression	NULL
by	NULL
PGE	NULL
,	NULL
was	NULL
totally	NULL
abolished	NULL
by	NULL
concentrations	NULL
of	NULL
MDL-12,330A	NULL
sufficient	NULL
to	NULL
completely	NULL
inhibit	NULL
cAMP	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Results	NULL
from	NULL
these	NULL
experiments	NULL
hence	NULL
demonstrated	NULL
that	NULL
PKA	NULL
was	NULL
an	NULL
essential	NULL
intracellular	NULL
second	NULL
messenger	NULL
participating	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-dependent	NULL
up-regulating	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Adenylate	NULL
cyclase	NULL
transforms	NULL
adenosine	NULL
triphosphate	NULL
(	NULL
ATP	NULL
)	NULL
in	NULL
cyclic	NULL
adenosine	NULL
monophosphate	NULL
(	NULL
cAMP	NULL
)	NULL
,	NULL
which	NULL
is	NULL
necessary	NULL
for	NULL
PKA	NULL
activity	NULL
.	NULL

Knowing	NULL
that	NULL
PKA	NULL
activation	NULL
is	NULL
negatively	NULL
modulated	NULL
by	NULL
phosphodiesterase	NULL
due	NULL
to	NULL
transformation	NULL
of	NULL
cAMP	NULL
to	NULL
5'-AMP	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
IBMX	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
phosphodiesterase	NULL
activity	NULL
(	NULL
60	NULL
)	NULL
.	NULL

It	NULL
is	NULL
hence	NULL
presumed	NULL
that	NULL
PGE	NULL
,	NULL
-induced	NULL
activation	NULL
of	NULL
PKA	NULL
should	NULL
be	NULL
sustained	NULL
for	NULL
longer	NULL
periods	NULL
of	NULL
time	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
IBMX	NULL
thus	NULL
resulting	NULL
in	NULL
a	NULL
greater	NULL
stimulation	NULL
of	NULL
HIV-1	NULL
LTR-dependent	NULL
gene	NULL
activity	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
caused	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
IBMX	NULL
indeed	NULL
led	NULL
to	NULL
a	NULL
dose-dependent	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PGE	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

This	NULL
PKA/cAMP	NULL
-dependent	NULL
activation	NULL
of	NULL
HIV-1	NULL
transcription	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
studies	NULL
(	NULL
61	NULL
,	NULL
62	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
treatment	NULL
of	NULL
1GS	NULL
cells	NULL
with	NULL
IBMX	NULL
alone	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
px	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR-dependent	NULL
reporter	NULL
gene	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
implication	NULL
of	NULL
Ca**	NULL
in	NULL
this	NULL
process	NULL
was	NULL
next	NULL
investigated	NULL
by	NULL
pretreating	NULL
1G5	NULL
cells	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
BAPTA/AM	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
pm	NULL
)	NULL
,	NULL
an	NULL
intracellular	NULL
Ca**	NULL
chelator	NULL
(	NULL
63	NULL
)	NULL
.	NULL

The	NULL
capacity	NULL
of	NULL
PGE	NULL
,	NULL
to	NULL
influence	NULL
HIV-LTR	NULL
activity	NULL
was	NULL
monitored	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Data	NULL
from	NULL
this	NULL
experiment	NULL
suggested	NULL
that	NULL
Ca**	NULL
``	NULL
was	NULL
partly	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
as	NULL
the	NULL
maximal	NULL
subcytotoxic	NULL
concentration	NULL
of	NULL
BAPTA/AM	NULL
used	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
could	NULL
not	NULL
totally	NULL
eliminate	NULL
PGE	NULL
,	NULL
-mediated	NULL
activating	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

Finally	NULL
a	NULL
newly	NULL
described	NULL
inhibitor	NULL
of	NULL
calcium	NULL
mobilization	NULL
,	NULL
carboxyamidotriazole	NULL
(	NULL
CAI	NULL
)	NULL
(	NULL
47	NULL
)	NULL
,	NULL
was	NULL
used	NULL
to	NULL
reinforce	NULL
the	NULL
implication	NULL
of	NULL
Ca®*	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-induced	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Data	NULL
obtained	NULL
from	NULL
this	NULL
set	NULL
of	NULL
experiments	NULL
confirmed	NULL
that	NULL
Ca**	NULL
is	NULL
indeed	NULL
an	NULL
important	NULL
component	NULL
of	NULL
the	NULL
PGE	NULL
,	NULL
-initiated	NULL
signaling	NULL
cascade	NULL
which	NULL
culminates	NULL
in	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR-dependent	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

3F	NULL
)	NULL
.	NULL

Altogether	NULL
,	NULL
the	NULL
use	NULL
of	NULL
specific	NULL
inhibitors	NULL
allowed	NULL
us	NULL
to	NULL
demonstrate	NULL
that	NULL
PKA	NULL
,	NULL
cAMP	NULL
,	NULL
and	NULL
Ca*	NULL
``	NULL
*	NULL
are	NULL
all	NULL
involved	NULL
to	NULL
some	NULL
degree	NULL
to	NULL
PGE	NULL
,	NULL
-dependent	NULL
positive	NULL
effect	NULL
on	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
.	NULL

To	NULL
mimic	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
1G5	NULL
cells	NULL
were	NULL
next	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
dibutyryl-cAMP	NULL
,	NULL
a	NULL
cAMP	NULL
analog	NULL
,	NULL
along	NULL
with	NULL
the	NULL
calcium	NULL
ionophore	NULL
,	NULL
ionomycin	NULL
.	NULL

Results	NULL
showed	NULL
that	NULL
treatment	NULL
of	NULL
1G5	NULL
cells	NULL
with	NULL
both	NULL
chemical	NULL
compounds	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
trigger	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
dose-dependent	NULL
significant	NULL
increase	NULL
in	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
was	NULL
seen	NULL
upon	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
increasing	NULL
concentrations	NULL
of	NULL
dibutyryl-cAMP	NULL
(	NULL
25	NULL
,	NULL
50	NULL
,	NULL
100	NULL
,	NULL
and	NULL
200	NULL
pum	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
specified	NULL
that	NULL
PMA	NULL
alone	NULL
was	NULL
strongly	NULL
activating	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
activity	NULL
because	NULL
this	NULL
agent	NULL
is	NULL
recognized	NULL
as	NULL
one	NULL
of	NULL
the	NULL
most	NULL
potent	NULL
activator	NULL
of	NULL
NF-xB	NULL
(	NULL
64	NULL
)	NULL
,	NULL
a	NULL
pleiotropic	NULL
transcription	NULL
factor	NULL
complex	NULL
known	NULL
as	NULL
a	NULL
good	NULL
inducer	NULL
of	NULL
HIV-1	NULL
expression	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
these	NULL
data	NULL
suggested	NULL
that	NULL
up-regulation	NULL
of	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27310	NULL
A	NULL
is	NULL
10	NULL
Fold	NULL
increase	NULL
L	NULL
5	NULL
T	NULL
#	NULL
00	NULL
47	NULL
1	NULL
a	NULL
5	NULL
E	NULL
3	NULL
k=	NULL
s	NULL
E	NULL
2-4	NULL
1	NULL
-I	NULL
T	NULL
T	NULL
l—J	NULL
'	NULL
I	NULL
,	NULL
_|a	NULL
.	NULL

0	NULL
I	NULL
I	NULL
T	NULL
I	NULL
MDL-12,330A	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
0	NULL
50	NULL
100	NULL
250	NULL
E	NULL
is	NULL
1	NULL
L	NULL
g	NULL
10-7	NULL
&	NULL
3	NULL
5	NULL
E	NULL
<	NULL
cl	NULL
E	NULL
5	NULL
-	NULL
T	NULL
T	NULL
4	NULL
T	NULL
1.	NULL
o	NULL
0	NULL
I	NULL
I	NULL
T	NULL
I	NULL
BAPTA/AM	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
0	NULL
1	NULL
5	NULL
10	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
B	NULL
is	NULL
»	NULL
10	NULL
-	NULL
1	NULL
#	NULL
$	NULL
5	NULL
2	NULL
3	NULL
0	NULL
A	NULL
5-4	NULL
7	NULL
-	NULL
IT	NULL
T_	NULL
[	NULL
1	NULL
a	NULL
ins	NULL
4	NULL
0	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
HA-1004	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
0	NULL
1	NULL
50°	NULL
100	NULL
_	NULL
20	NULL
D	NULL
so	NULL
40	NULL
-	NULL
T	NULL
1	NULL
B	NULL
$	NULL
s-	NULL
T	NULL
tL	NULL
|	NULL
1	NULL
3	NULL
20	NULL
-	NULL
1	NULL
E	NULL
10	NULL
-|	NULL
-+	NULL
0	NULL
T	NULL
1	NULL
T	NULL
T	NULL
IBMX	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
0	NULL
A	NULL
5	NULL
10	NULL
Fos	NULL
I	NULL
«	NULL
4|	NULL
|	NULL
&	NULL
$	NULL
5	NULL
£	NULL
47	NULL
M	NULL
g	NULL
I	NULL
E	NULL
3	NULL
2-	NULL
T	NULL
0	NULL
I	NULL
T	NULL
I	NULL
I	NULL
CAL	NULL
(	NULL
M	NULL
)	NULL
:	NULL
-	NULL
o	NULL
0.4	NULL
1	NULL
10	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Identification	NULL
of	NULL
second	NULL
messengers	NULL
implicated	NULL
in	NULL
PGE	NULL
,	NULL
-mediated	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
.	NULL

1G5	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
H7	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
uM	NULL
)	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
,	NULL
HA-1004	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
10	NULL
,	NULL
and	NULL
20	NULL
pM	NULL
)	NULL
(	NULL
panel	NULL
B	NULL
)	NULL
,	NULL
MDL-12,330A	NULL
(	NULL
50	NULL
,	NULL
100	NULL
,	NULL
and	NULL
250	NULL
uM	NULL
)	NULL
(	NULL
panel	NULL
C	NULL
)	NULL
,	NULL
IBMX	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
pM	NULL
)	NULL
(	NULL
panel	NULL
D	NULL
)	NULL
,	NULL
BAPTA/AM	NULL
(	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
pM	NULL
)	NULL
(	NULL
panel	NULL
E	NULL
)	NULL
,	NULL
and	NULL
for	NULL
16	NULL
h	NULL
with	NULL
CAI	NULL
(	NULL
0.1	NULL
,	NULL
1.0	NULL
,	NULL
and	NULL
10	NULL
uM	NULL
)	NULL
(	NULL
panel	NULL
F	NULL
)	NULL
prior	NULL
to	NULL
treatment	NULL
for	NULL
8	NULL
h	NULL
with	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
evaluated	NULL
for	NULL
luciferase	NULL
activity	NULL
by	NULL
scintillation	NULL
count	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
(	NULL
*	NULL
S.D	NULL
.	NULL
)	NULL

of	NULL
four	NULL
determinations	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
relative	NULL
to	NULL
basal	NULL
luciferase	NULL
activity	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
considered	NULL
as	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

HIV-1	NULL
LTR	NULL
activity	NULL
requires	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
addition	NULL
to	NULL
cAMP-	NULL
and	NULL
calcium-dependent	NULL
signaling	NULL
pathways	NULL
.	NULL

NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
-independent	NULL
Signaling	NULL
Pathways	NULL
Are	NULL
Involved	NULL
in	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
by	NULL
PGE	NULL
,	NULL
-To	NULL
define	NULL
the	NULL
region	NULL
(	NULL
s	NULL
)	NULL
required	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
transcription	NULL
by	NULL
PGE	NULL
at	NULL
the	NULL
molecular	NULL
level	NULL
,	NULL
the	NULL
parental	NULL
Jurkat	NULL
E6.1	NULL
cell	NULL
line	NULL
was	NULL
transiently	NULL
transfected	NULL
with	NULL
different	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
constructs	NULL
carrying	NULL
either	NULL
the	NULL
full-length	NULL
(	NULL
pLTR-LUC	NULL
)	NULL
or	NULL
modified	NULL
versions	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
(	NULL
pme	NULL
«	NULL
BLTR-LUC	NULL
and	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
)	NULL
.	NULL

These	NULL
latter	NULL
constructs	NULL
either	NULL
contained	NULL
the	NULL
complete	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
mutated	NULL
at	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
(	NULL
pm	NULL
«	NULL
BLTR-LUC	NULL
)	NULL
or	NULL
the	NULL
minimal	NULL
HIV-1	NULL
«	NULL
B	NULL
region	NULL
and	NULL
a	NULL
TATA	NULL
box	NULL
(	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
)	NULL
.	NULL

Transiently	NULL
transfected	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
were	NULL
then	NULL
stimulated	NULL
with	NULL
TNF-a	NULL
,	NULL
PHA/PMA	NULL
,	NULL
or	NULL
PGE	NULL
,	NULL
for	NULL
8	NULL
h.	NULL
In	NULL
these	NULL
experiments	NULL
,	NULL
stimulation	NULL
with	NULL
TNF-a	NULL
and	NULL
PHA/PMA	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
controls	NULL
since	NULL
TNF-	NULL
«	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
HIV-1	NULL
transcription	NULL
exclusively	NULL
via	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
66	NULL
)	NULL
,	NULL
while	NULL
the	NULL
combination	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
can	NULL
enhance	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
via	NULL
both	NULL
NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
-independent	NULL
signaling	NULL
pathways	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
13.7-	NULL
,	NULL
83.3-	NULL
,	NULL
and	NULL
12.1-fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
for	NULL
the	NULL
full-length	NULL
HIV-1	NULL
LTR	NULL
(	NULL
pLTR-LUC	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TNF	NULL
-	NULL
«	NULL
,	NULL
PHA/	NULL
PMA	NULL
,	NULL
and	NULL
PGE	NULL
,	NULL
respectively	NULL
.	NULL

With	NULL
the	NULL
molecular	NULL
construct	NULL
pm	NULL
«	NULL
BLTR-LUC	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
activity	NULL
was	NULL
detected	NULL
with	NULL
TNF-	NULL
@	NULL
,	NULL
while	NULL
PHA/PMA	NULL
was	NULL
still	NULL
inducing	NULL
HIV-1	NULL
LTR-dependent	NULL
luciferase	NULL
activity	NULL
(	NULL
8.5-fold	NULL
increase	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
luciferase-encoding	NULL
vector	NULL
mutated	NULL
at	NULL
both	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
of	NULL
the	NULL
LTR	NULL
was	NULL
still	NULL
responding	NULL
to	NULL
PGE	NULL
,	NULL
,	NULL
although	NULL
at	NULL
a	NULL
slightly	NULL
lower	NULL
level	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
HIV-1	NULL
LTR	NULL
construct	NULL
(	NULL
8.8-	NULL
versus	NULL
12.1-fold	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
was	NULL
repeated	NULL
several	NULL
times	NULL
and	NULL
gave	NULL
consistent	NULL
results	NULL
.	NULL

Therefore	NULL
,	NULL
data	NULL
from	NULL
experiments	NULL
conducted	NULL
with	NULL
pLTR-LUC	NULL
and	NULL
pm	NULL
«	NULL
BLTR-LUC	NULL
were	NULL
indicating	NULL
that	NULL
PGE	NULL
,	NULL
-mediated	NULL
positive	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR-driven	NULL
activity	NULL
required	NULL
both	NULL
NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
-independent	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
nuclear	NULL
translocation	NULL
and	NULL
activation	NULL
of	NULL
NF-kB	NULL
was	NULL
indeed	NULL
induced	NULL
by	NULL
PGE	NULL
,	NULL
cells	NULL
were	NULL
transiently	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
80	NULL
--	NULL
60	NULL
40	NULL
Fold	NULL
increase	NULL
20	NULL
0	NULL
I	NULL
1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
dbcAMP	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
0	NULL
0	NULL
25	NULL
50	NULL
100	NULL
200	NULL
jonomycin	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
:	NULL
-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
:	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Activation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
dibutyryl-cAMP	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
PMA	NULL
.	NULL

1G5	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
or	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
ionomycin	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
increasing	NULL
concentrations	NULL
of	NULL
dibutyryl-cAMP	NULL
(	NULL
0	NULL
,	NULL
25	NULL
,	NULL
50	NULL
,	NULL
100	NULL
,	NULL
and	NULL
200	NULL
pM	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
evaluated	NULL
for	NULL
luciferase	NULL
activity	NULL
by	NULL
scintillation	NULL
count	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
(	NULL
+	NULL
S.D	NULL
.	NULL
)	NULL

of	NULL
four	NULL
determinations	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
relative	NULL
to	NULL
basal	NULL
luciferase	NULL
activity	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
considered	NULL
as	NULL
1	NULL
)	NULL
.	NULL

transfected	NULL
with	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
.	NULL

It	NULL
should	NULL
be	NULL
specified	NULL
that	NULL
this	NULL
vector	NULL
allows	NULL
monitoring	NULL
of	NULL
HIV-1	NULL
activation	NULL
almost	NULL
exclusively	NULL
via	NULL
NF-	NULL
«	NULL
B-dependent	NULL
mechanism	NULL
.	NULL

Indeed	NULL
,	NULL
this	NULL
vector	NULL
is	NULL
made	NULL
of	NULL
the	NULL
minimal	NULL
HIV-1	NULL
NF-	NULL
«	NULL
B-binding	NULL
domains	NULL
and	NULL
a	NULL
TATA	NULL
box	NULL
driving	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
(	NULL
46	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
a	NULL
15.4-fold	NULL
increase	NULL
in	NULL
HIV-1	NULL
LTR-dependent	NULL
reporter	NULL
gene	NULL
activity	NULL
was	NULL
seen	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PGE	NULL
,	NULL
thereby	NULL
confirming	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
directly	NULL
involved	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-dependent	NULL
activating	NULL
effect	NULL
on	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
.	NULL

To	NULL
further	NULL
substantiate	NULL
the	NULL
participation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
PGE	NULL
,	NULL
-mediated	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
transcription	NULL
,	NULL
Jurkat	NULL
E6.1	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pNF-	NULL
«	NULL
B-LUC	NULL
,	NULL
a	NULL
vector	NULL
made	NULL
of	NULL
five	NULL
consensus	NULL
binding	NULL
sites	NULL
for	NULL
NF-xB	NULL
,	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
PGE	NULL
,	NULL
.	NULL

The	NULL
implication	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-mediated	NULL
activating	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
was	NULL
again	NULL
clearly	NULL
shown	NULL
using	NULL
this	NULL
«	NULL
B-driven	NULL
reporter	NULL
gene	NULL
construct	NULL
(	NULL
17.5-fold	NULL
increase	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
also	NULL
examined	NULL
by	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
band	NULL
specific	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
that	NULL
is	NULL
induced	NULL
following	NULL
the	NULL
treatment	NULL
for	NULL
1	NULL
h	NULL
with	NULL
either	NULL
PGE	NULL
,	NULL
or	NULL
TNF-a	NULL
(	NULL
Zanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
band	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
eliminated	NULL
by	NULL
competition	NULL
experiment	NULL
with	NULL
unlabeled	NULL
probe	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

These	NULL
results	NULL
were	NULL
thus	NULL
reinforcing	NULL
the	NULL
notion	NULL
that	NULL
PGE	NULL
,	NULL
is	NULL
up-regulating	NULL
HIV-1	NULL
LTR	NULL
dependent	NULL
activity	NULL
also	NULL
through	NULL
a	NULL
NF-	NULL
«	NULL
B-dependent	NULL
mechanism	NULL
.	NULL

It	NULL
has	NULL
recently	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
can	NULL
synergize	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
the	NULL
viral	NULL
transactivating	NULL
protein	NULL
Tat	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
HIV-1	NULL
following	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sequences	NULL
(	NULL
67	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
evaluated	NULL
the	NULL
putative	NULL
implication	NULL
of	NULL
NFAT	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-induced	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
.	NULL

Using	NULL
a	NULL
molecular	NULL
construct	NULL
made	NULL
of	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
placed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
minimal	NULL
IL-2	NULL
promoter	NULL
containing	NULL
three	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
NFAT	NULL
-binding	NULL
site	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
showed	NULL
no	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
In	NULL
contrast	NULL
,	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
reporter	NULL
gene	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
PMA/PHA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
could	NULL
conclude	NULL
from	NULL
these	NULL
data	NULL
that	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT	NULL
was	NULL
not	NULL
playing	NULL
a	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
transcription	NULL
.	NULL

Surface	NULL
Expression	NULL
of	NULL
the	NULL
Human	NULL
PGE	NULL
,	NULL
Receptor	NULL
EP	NULL
,	NULL
Subtype	NULL
in	NULL
the	NULL
Studied	NULL
T	NULL
Lymphoid	NULL
Lineages-PGE	NULL
,	NULL
is	NULL
known	NULL
to	NULL
bind	NULL
to	NULL
specific	NULL
protein	NULL
receptors	NULL
on	NULL
a	NULL
large	NULL
array	NULL
of	NULL
target	NULL
cells	NULL
.	NULL

27311	NULL
A	NULL
100	NULL
T	NULL
O	NULL
TNF	NULL
454.9	NULL
+	NULL
15.3	NULL
507	NULL
Fold	NULL
increase	NULL
257	NULL
0—	NULL
C	NULL
a	NULL
J	NULL
Lo	NULL
3	NULL
2	NULL
A	NULL
pd	NULL
@	NULL
@	NULL
&	NULL
Pu	NULL
a	NULL
E1	NULL
£	NULL
2	NULL
B	NULL
s	NULL
n	NULL
to	NULL
T	NULL
40-	NULL
T	NULL
¥	NULL
he	NULL
J-	NULL
C	NULL
P	NULL
3	NULL
so-	NULL
©	NULL
5	NULL
£	NULL
k=l	NULL
3	NULL
207	NULL
T	NULL
L	NULL
10	NULL
&	NULL
TNF-q	NULL
_	NULL
PHA/PMA	NULL
PGE	NULL
,	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

NF-	NULL
«	NULL
B-dependent	NULL
and	NULL
-independent	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
by	NULL
PGE	NULL
,	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pLTR-LUC	NULL
,	NULL
pm	NULL
«	NULL
BLTR-LUC	NULL
,	NULL
or	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
and	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
TNF-	NULL
«	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
,	NULL
PHA/PMA	NULL
(	NULL
8	NULL
ug/ml	NULL
and	NULL
20	NULL
ng/ml	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
or	NULL
PGE	NULL
,	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
.	NULL

B	NULL
,	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pNF-	NULL
«	NULL
B-LUC	NULL
and	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
TNF-	NULL
«	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
,	NULL
PHA/PMA	NULL
(	NULL
8	NULL
ug/ml	NULL
and	NULL
20	NULL
ng/ml	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
and	NULL
PGE	NULL
,	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
evaluated	NULL
for	NULL
luciferase	NULL
activity	NULL
by	NULL
scintillation	NULL
count	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
(	NULL
+	NULL
S.D	NULL
.	NULL
)	NULL

of	NULL
four	NULL
determinations	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
relative	NULL
to	NULL
basal	NULL
luciferase	NULL
activity	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
considered	NULL
as	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Previous	NULL
cDNA	NULL
cloning	NULL
and	NULL
pharmacologic	NULL
experiments	NULL
have	NULL
identified	NULL
six	NULL
different	NULL
PGE	NULL
,	NULL
receptors	NULL
(	NULL
EPs	NULL
)	NULL
(	NULL
68	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analyses	NULL
were	NULL
then	NULL
performed	NULL
to	NULL
evaluate	NULL
PGE	NULL
,	NULL
receptor	NULL
(	NULL
s	NULL
)	NULL
expression	NULL
on	NULL
the	NULL
T	NULL
lymphoid	NULL
cell	NULL
lines	NULL
used	NULL
in	NULL
the	NULL
present	NULL
study	NULL
.	NULL

The	NULL
cDNAs	NULL
for	NULL
hEP	NULL
,	NULL
,	NULL
hEP	NULL
;	NULL
,	NULL
hEP	NULL
;	NULL
,	NULL
and	NULL
hEP	NULL
,	NULL
were	NULL
hybridized	NULL
with	NULL
total	NULL
RNA	NULL
from	NULL
1G5	NULL
and	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
.	NULL

Results	NULL
indicated	NULL
that	NULL
the	NULL
hEP	NULL
,	NULL
gene	NULL
was	NULL
expressed	NULL
on	NULL
both	NULL
1GS5	NULL
and	NULL
Jurkat	NULL
E6.1	NULL
cell	NULL
lines	NULL
,	NULL
while	NULL
EP	NULL
;	NULL
,	NULL
EP	NULL
;	NULL
,	NULL
and	NULL
EP	NULL
;	NULL
subtype	NULL
receptors	NULL
were	NULL
not	NULL
expressed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
was	NULL
also	NULL
carried	NULL
out	NULL
with	NULL
a	NULL
polyclonal	NULL
antibody	NULL
specific	NULL
for	NULL
EP	NULL
,	NULL
receptor	NULL
and	NULL
confirmed	NULL
its	NULL
presence	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
Jurkat	NULL
E6.1	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
and	NULL
1G5	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
cells	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
the	NULL
prostaglandin	NULL
receptor	NULL
on	NULL
T	NULL
lymphoid	NULL
1G5	NULL
cells	NULL
was	NULL
directly	NULL
addressed	NULL
using	NULL
a	NULL
subtype	NULL
selective	NULL
pharmacologic	NULL
antagonist	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
1G5	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
AH	NULL
23848B	NULL
(	NULL
30	NULL
uM	NULL
)	NULL
,	NULL
a	NULL
selective	NULL
antagonist	NULL
of	NULL
human	NULL
EP	NULL
,	NULL
receptor	NULL
,	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
PGE	NULL
.	NULL

AH	NULL
23848B	NULL
was	NULL
found	NULL
to	NULL
abrogate	NULL
PGE	NULL
,	NULL
-mediated	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
in	NULL
1G5	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Altogether	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
hEP	NULL
,	NULL
receptor	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-mediated	NULL
activating	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
in	NULL
T	NULL
lymphoid	NULL
cells	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27312	NULL
1	NULL
2	NULL
3	NULL
4	NULL
b	NULL
(	NULL
6	NULL
NF-	NULL
«	NULL
B	NULL
-	NULL
ji	NULL
Free	NULL
probe	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Nuclear	NULL
translocation	NULL
and	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
PGE	NULL
,	NULL
.	NULL

1G5	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
either	NULL
100	NULL
nM	NULL
PGE	NULL
,	NULL
or	NULL
2	NULL
ng/ml	NULL
TNF-a	NULL
(	NULL
positive	NULL
control	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
were	NULL
next	NULL
incubated	NULL
with	NULL
a	NULL
*	NULL
``	NULL
P-end-labeled	NULL
synthetic	NULL
double-stranded	NULL
NF-	NULL
«	NULL
B	NULL
probe	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
are	NULL
negative	NULL
controls	NULL
containing	NULL
no	NULL
extracts	NULL
or	NULL
extracts	NULL
from	NULL
untreated	NULL
cells	NULL
,	NULL
respectively	NULL
.	NULL

Lane	NULL
3	NULL
represents	NULL
a	NULL
positive	NULL
control	NULL
containing	NULL
cells	NULL
stimulated	NULL
with	NULL
TNF-a	NULL
(	NULL
2	NULL
ng/ml	NULL
)	NULL
,	NULL
while	NULL
lane	NULL
4	NULL
are	NULL
cells	NULL
treated	NULL
with	NULL
PGE	NULL
,	NULL
.	NULL

Lanes	NULL
5	NULL
and	NULL
6	NULL
represent	NULL
a	NULL
100	NULL
X	NULL
competition	NULL
with	NULL
the	NULL
unlabeled	NULL
probe	NULL
for	NULL
NF-kB	NULL
with	NULL
TNF-a	NULL
and	NULL
PGE	NULL
,	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
specific	NULL
complex	NULL
bound	NULL
by	NULL
the	NULL
«	NULL
B	NULL
site	NULL
probe	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
on	NULL
the	NULL
left	NULL
side	NULL
.	NULL

g	NULL
A	NULL
&	NULL
G	NULL
10°	NULL
10	NULL
10°	NULL
10°	NULL
10°	NULL
Relative	NULL
cell	NULL
number	NULL
O	NULL
|	NULL
--	NULL
,	NULL
.	NULL

mmmmom-r-mrrmm	NULL
10°	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
Fluorescence	NULL
intensity	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Cytometry	NULL
analysis	NULL
of	NULL
PGE	NULL
,	NULL
receptor	NULL
subtype	NULL
4	NULL
on	NULL
studied	NULL
cell	NULL
lines	NULL
.	NULL

Flow	NULL
cytometric	NULL
analyses	NULL
were	NULL
performed	NULL
using	NULL
a	NULL
saturating	NULL
concentration	NULL
of	NULL
polyclonal	NULL
anti-human	NULL
EP	NULL
,	NULL
antibody	NULL
in	NULL
combination	NULL
with	NULL
fluorescein	NULL
isothiocyanate-labeled	NULL
chicken	NULL
anti-rabbit	NULL
IgG	NULL
antibody	NULL
(	NULL
panel	NULL
A	NULL
,	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
;	NULL
and	NULL
panel	NULL
B	NULL
,	NULL
1GS5	NULL
cells	NULL
)	NULL
.	NULL

The	NULL
solid	NULL
lines	NULL
represent	NULL
background	NULL
fluorescence	NULL
.	NULL

DISCUSSION	NULL
Immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
are	NULL
triggered	NULL
by	NULL
microorganisms	NULL
such	NULL
as	NULL
bacteria	NULL
,	NULL
viruses	NULL
,	NULL
and	NULL
protozoan	NULL
,	NULL
all	NULL
known	NULL
to	NULL
be	NULL
potential	NULL
opportunistic	NULL
pathogens	NULL
in	NULL
HIV-1-posi-tive	NULL
patients	NULL
.	NULL

The	NULL
formation	NULL
and	NULL
production	NULL
of	NULL
elevated	NULL
levels	NULL
of	NULL
inflammatory	NULL
mediators	NULL
such	NULL
as	NULL
PGE	NULL
,	NULL
is	NULL
a	NULL
hallmark	NULL
of	NULL
the	NULL
HIV-1	NULL
infection	NULL
(	NULL
28-80	NULL
)	NULL
.	NULL

Prostaglandins	NULL
play	NULL
a	NULL
role	NULL
in	NULL
disease	NULL
exacerbation	NULL
by	NULL
directly	NULL
altering	NULL
T-cell	NULL
functions	NULL
or	NULL
macro	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
15	NULL
i	NULL
z	NULL
10	NULL
-	NULL
T	NULL
2	NULL
T	NULL
2	NULL
L	NULL
3	NULL
A	NULL
-	NULL
54	NULL
0	NULL
I	NULL
T	NULL
T	NULL
T	NULL
AH	NULL
23848B	NULL
(	NULL
uM	NULL
)	NULL
:	NULL
0	NULL
5	NULL
15	NULL
30	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Pharmacological	NULL
study	NULL
of	NULL
the	NULL
PGE	NULL
,	NULL
receptor	NULL
with	NULL
the	NULL
selective	NULL
antagonist	NULL
AH	NULL
23848B	NULL
.	NULL

1GS5	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
the	NULL
selective	NULL
antagonist	NULL
of	NULL
human	NULL
EP	NULL
,	NULL
AH	NULL
23848B	NULL
(	NULL
0	NULL
,	NULL
5	NULL
,	NULL
15	NULL
,	NULL
and	NULL
30	NULL
uM	NULL
)	NULL
for	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
incubation	NULL
for	NULL
8	NULL
h	NULL
with	NULL
PGE	NULL
,	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
.	NULL

Next	NULL
,	NULL
luciferase	NULL
activity	NULL
was	NULL
monitored	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
means	NULL
(	NULL
+	NULL
S.D	NULL
.	NULL
)	NULL

of	NULL
four	NULL
determinations	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
relative	NULL
to	NULL
basal	NULL
luciferase	NULL
activity	NULL
in	NULL
untreated	NULL
control	NULL
cells	NULL
(	NULL
considered	NULL
as	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

phage	NULL
activation	NULL
.	NULL

Although	NULL
it	NULL
was	NULL
thought	NULL
that	NULL
PGE	NULL
,	NULL
is	NULL
primarily	NULL
an	NULL
immunosuppressive	NULL
molecule	NULL
that	NULL
acts	NULL
as	NULL
a	NULL
down-regulator	NULL
of	NULL
many	NULL
aspects	NULL
of	NULL
B-	NULL
and	NULL
T-cell	NULL
function	NULL
and	NULL
proliferation	NULL
,	NULL
recent	NULL
findings	NULL
support	NULL
a	NULL
role	NULL
for	NULL
PGE	NULL
,	NULL
as	NULL
a	NULL
potentiator	NULL
of	NULL
immunoglobulin	NULL
class	NULL
switching	NULL
and	NULL
cytokine	NULL
and	NULL
cytokine	NULL
receptor	NULL
synthesis	NULL
(	NULL
15	NULL
)	NULL
.	NULL

This	NULL
PGE	NULL
,	NULL
-dependent	NULL
positive	NULL
effect	NULL
on	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
the	NULL
observation	NULL
that	NULL
higher	NULL
levels	NULL
of	NULL
PGE	NULL
,	NULL
are	NULL
detected	NULL
in	NULL
HIV-1-infected	NULL
individuals	NULL
(	NULL
2-5-fold	NULL
increase	NULL
)	NULL
have	NULL
been	NULL
the	NULL
compelling	NULL
force	NULL
for	NULL
our	NULL
investigation	NULL
.	NULL

Knowing	NULL
that	NULL
PGE	NULL
,	NULL
is	NULL
a	NULL
good	NULL
inducer	NULL
of	NULL
cAMP	NULL
and	NULL
that	NULL
a	NULL
4-fold	NULL
increase	NULL
in	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
is	NULL
seen	NULL
in	NULL
asymptomatic	NULL
HIV-l-seropositive	NULL
subjects	NULL
as	NULL
compared	NULL
with	NULL
uninfected	NULL
controls	NULL
(	NULL
69	NULL
)	NULL
,	NULL
it	NULL
was	NULL
thus	NULL
of	NULL
prime	NULL
importance	NULL
to	NULL
study	NULL
the	NULL
putative	NULL
effect	NULL
of	NULL
PGE	NULL
,	NULL
on	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
.	NULL

We	NULL
therefore	NULL
asked	NULL
whether	NULL
the	NULL
proinflammatory	NULL
PGE	NULL
,	NULL
molecule	NULL
had	NULL
the	NULL
ability	NULL
to	NULL
modulate	NULL
HIV-1	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
particular	NULL
cell	NULL
type	NULL
was	NULL
chosen	NULL
since	NULL
T	NULL
cells	NULL
are	NULL
considered	NULL
to	NULL
be	NULL
a	NULL
major	NULL
cellular	NULL
reservoir	NULL
for	NULL
HIV-1	NULL
in	NULL
the	NULL
human	NULL
peripheral	NULL
blood	NULL
(	NULL
70	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
present	NULL
evidence	NULL
indicating	NULL
that	NULL
PGE	NULL
up-regulates	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
indicative	NULL
of	NULL
an	NULL
optimal	NULL
signal	NULL
after	NULL
6	NULL
to	NULL
8	NULL
h	NULL
of	NULL
treatment	NULL
.	NULL

This	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
time	NULL
kinetics	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
by	NULL
PMA	NULL
,	NULL
PHA	NULL
,	NULL
and	NULL
TNF-a	NULL
agents	NULL
which	NULL
directly	NULL
act	NULL
on	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Although	NULL
we	NULL
can	NULL
not	NULL
refute	NULL
a	NULL
possible	NULL
indirect	NULL
mechanism	NULL
for	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
by	NULL
PGE	NULL
,	NULL
which	NULL
would	NULL
involve	NULL
production	NULL
of	NULL
cytokines	NULL
,	NULL
time	NULL
course	NULL
experiments	NULL
suggested	NULL
that	NULL
a	NULL
more	NULL
direct	NULL
process	NULL
might	NULL
be	NULL
at	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
PGE	NULL
,	NULL
on	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
specific	NULL
synergistic	NULL
HIV-1	NULL
LTR	NULL
activation	NULL
was	NULL
observed	NULL
using	NULL
both	NULL
PGE	NULL
,	NULL
and	NULL
TNF	NULL
-	NULL
«	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

This	NULL
might	NULL
be	NULL
accounted	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
effect	NULL
exerted	NULL
by	NULL
TNF-a	NULL
«	NULL
is	NULL
exclusively	NULL
via	NULL
NF-KB	NULL
,	NULL
while	NULL
PGE	NULL
,	NULL
acts	NULL
also	NULL
on	NULL
region	NULL
(	NULL
s	NULL
)	NULL
other	NULL
than	NULL
NF-B	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Previously	NULL
described	NULL
synergistic	NULL
activation	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
other	NULL
factors	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
66	NULL
,	NULL
67	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
by	NULL
PGE	NULL
,	NULL
thus	NULL
support	NULL
a	NULL
previous	NULL
cellular	NULL
study	NULL
showing	NULL
a	NULL
2.5-fold	NULL
increase	NULL
in	NULL
virus	NULL
production	NULL
following	NULL
the	NULL
addition	NULL
of	NULL
exogeneous	NULL
PGE	NULL
,	NULL
to	NULL
MT-4	NULL
cells	NULL
acutely	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
43	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
involvement	NULL
of	NULL
specific	NULL
intracellular	NULL
second	NULL
messengers	NULL
in	NULL
PGE	NULL
,	NULL
-mediated	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
has	NULL
been	NULL
dissected	NULL
using	NULL
several	NULL
signal	NULL
transduction	NULL
inhibitors	NULL
.	NULL

Experiments	NULL
with	NULL
indomethacin	NULL
,	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
the	NULL
cyclooxygenase	NULL
pathway	NULL
and	NULL
thus	NULL
of	NULL
PGE	NULL
,	NULL
pro	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
duction	NULL
,	NULL
suggest	NULL
that	NULL
only	NULL
exogeneous	NULL
PGE	NULL
,	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
.	NULL

These	NULL
results	NULL
were	NULL
expected	NULL
based	NULL
on	NULL
studies	NULL
that	NULL
T	NULL
cells	NULL
had	NULL
a	NULL
limited	NULL
capacity	NULL
to	NULL
metabolize	NULL
arachidonic	NULL
acid	NULL
to	NULL
prostaglandins	NULL
(	NULL
71-73	NULL
)	NULL
.	NULL

An	NULL
earlier	NULL
report	NULL
indicated	NULL
that	NULL
interaction	NULL
between	NULL
PGE	NULL
,	NULL
and	NULL
an	NULL
adenylate	NULL
cyclase-coupled	NULL
stimulatory	NULL
receptor	NULL
leads	NULL
to	NULL
activation	NULL
of	NULL
adenylate	NULL
cyclase	NULL
,	NULL
hydrolysis	NULL
of	NULL
ATP	NULL
,	NULL
enhanced	NULL
turnover	NULL
of	NULL
intracellular	NULL
cAMP	NULL
,	NULL
and	NULL
binding	NULL
to	NULL
PKA	NULL
(	NULL
74	NULL
)	NULL
.	NULL

Our	NULL
findings	NULL
are	NULL
clearly	NULL
supportive	NULL
of	NULL
this	NULL
signaling	NULL
cascade	NULL
since	NULL
we	NULL
found	NULL
that	NULL
PGE	NULL
,	NULL
-induced	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
LTR	NULL
dependent	NULL
activity	NULL
requires	NULL
the	NULL
participation	NULL
of	NULL
adenylate	NULL
cyclase	NULL
,	NULL
cAMP	NULL
,	NULL
and	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A-D	NULL
)	NULL
.	NULL

Using	NULL
MT-4	NULL
cells	NULL
,	NULL
another	NULL
group	NULL
has	NULL
shown	NULL
that	NULL
elevation	NULL
of	NULL
cAMP	NULL
levels	NULL
resulted	NULL
in	NULL
HIV-1	NULL
replication	NULL
(	NULL
62	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
well	NULL
known	NULL
that	NULL
cAMP-dependent	NULL
pathways	NULL
regulate	NULL
the	NULL
immune	NULL
effector	NULL
functions	NULL
of	NULL
lymphocytes	NULL
and	NULL
macrophages	NULL
.	NULL

For	NULL
example	NULL
,	NULL
during	NULL
immune	NULL
response	NULL
,	NULL
cAMP	NULL
exhibits	NULL
positive	NULL
regulatory	NULL
effects	NULL
at	NULL
low	NULL
concentrations	NULL
whereas	NULL
inhibitory	NULL
effects	NULL
are	NULL
seen	NULL
at	NULL
high	NULL
concentrations	NULL
(	NULL
75	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
earlier	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
PGE	NULL
,	NULL
interaction	NULL
with	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
resulted	NULL
in	NULL
an	NULL
elevation	NULL
of	NULL
the	NULL
cAMP	NULL
level	NULL
(	NULL
35	NULL
)	NULL
and	NULL
that	NULL
such	NULL
elevated	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
were	NULL
responsible	NULL
for	NULL
the	NULL
proliferative	NULL
disturbances	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
76-78	NULL
)	NULL
.	NULL

Data	NULL
from	NULL
our	NULL
experiment	NULL
with	NULL
the	NULL
calcium	NULL
chelator	NULL
BAPTA/AM	NULL
and	NULL
the	NULL
calcium	NULL
inhibitor	NULL
CAI	NULL
are	NULL
suggestive	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
Ca**	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-induced	NULL
activation	NULL
of	NULL
HIV-1	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

However	NULL
,	NULL
given	NULL
that	NULL
there	NULL
is	NULL
no	NULL
published	NULL
report	NULL
indicating	NULL
Ca**	NULL
influx	NULL
through	NULL
the	NULL
EP	NULL
,	NULL
receptor	NULL
,	NULL
our	NULL
results	NULL
with	NULL
BAPTA/AM	NULL
and	NULL
CAI	NULL
,	NULL
two	NULL
inhibitors	NULL
of	NULL
intracellular	NULL
calcium	NULL
mobilization	NULL
,	NULL
lead	NULL
us	NULL
to	NULL
postulate	NULL
that	NULL
PGE	NULL
,	NULL
could	NULL
generate	NULL
calcium	NULL
release	NULL
from	NULL
intracellular	NULL
storage	NULL
organelles	NULL
.	NULL

All	NULL
these	NULL
results	NULL
were	NULL
supported	NULL
by	NULL
data	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
indicating	NULL
that	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
requires	NULL
the	NULL
implication	NULL
of	NULL
cAMP	NULL
and	NULL
calcium	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
participation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
.	NULL

Several	NULL
agents	NULL
known	NULL
as	NULL
potent	NULL
activators	NULL
of	NULL
HIV-1	NULL
transcription	NULL
(	NULL
e.g	NULL
.	NULL

PMA	NULL
,	NULL
PHA	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
anti-CD3	NULL
antibody	NULL
)	NULL
are	NULL
all	NULL
acting	NULL
through	NULL
a	NULL
common	NULL
mechanism	NULL
,	NULL
namely	NULL
via	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
enhancer	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
79	NULL
)	NULL
.	NULL

This	NULL
transcription	NULL
factor	NULL
is	NULL
sequestered	NULL
in	NULL
the	NULL
cytoplasm	NULL
due	NULL
to	NULL
its	NULL
physical	NULL
association	NULL
with	NULL
the	NULL
inhibitor	NULL
named	NULL
IxB	NULL
.	NULL

NF-KB	NULL
is	NULL
a	NULL
pleiotropic	NULL
transcription	NULL
factor	NULL
that	NULL
controls	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
genes	NULL
,	NULL
including	NULL
cytokines	NULL
such	NULL
as	NULL
IL-1	NULL
,	NULL
IL-2	NULL
,	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
interferon-	NULL
$	NULL
,	NULL
and	NULL
TNF-a	NULL
@	NULL
,	NULL
as	NULL
well	NULL
as	NULL
known	NULL
genes	NULL
for	NULL
some	NULL
cell	NULL
adhesion	NULL
molecules	NULL
including	NULL
ICAM-1	NULL
and	NULL
VCAM-1	NULL
.	NULL

Its	NULL
importance	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
has	NULL
been	NULL
stated	NULL
in	NULL
numerous	NULL
studies	NULL
(	NULL
80	NULL
)	NULL
.	NULL

Results	NULL
from	NULL
mobility	NULL
shift	NULL
assays	NULL
suggest	NULL
that	NULL
the	NULL
PGE	NULL
,	NULL
-mediated	NULL
effect	NULL
on	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
is	NULL
due	NULL
to	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
PGE	NULL
,	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
previous	NULL
demonstration	NULL
that	NULL
PGE	NULL
,	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
macrophage-like	NULL
cell	NULL
line	NULL
J774	NULL
(	NULL
81	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
we	NULL
have	NULL
noticed	NULL
that	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Ca**	NULL
are	NULL
key	NULL
elements	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
effect	NULL
on	NULL
HIV-1	NULL
transcription	NULL
is	NULL
of	NULL
interest	NULL
considering	NULL
that	NULL
calcineurin	NULL
,	NULL
a	NULL
Ca**/	NULL
calmodulin-dependent	NULL
serine/threonine	NULL
protein	NULL
phosphatase	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
the	NULL
inactivation	NULL
of	NULL
IxB	NULL
(	NULL
82	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
researchers	NULL
had	NULL
earlier	NULL
found	NULL
that	NULL
cAMP-mediated	NULL
enhancement	NULL
of	NULL
PKA	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
dissociation	NULL
of	NULL
IxB	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
79	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
revealed	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
regulated	NULL
through	NULL
phosphorylation	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
by	NULL
PKA	NULL
which	NULL
is	NULL
directly	NULL
regulated	NULL
by	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
(	NULL
83	NULL
)	NULL
.	NULL

Our	NULL
experiments	NULL
hence	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
PGE	NULL
,	NULL
might	NULL
be	NULL
activating	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
via	NULL
cAMP/PKA	NULL
and	NULL
calcium	NULL
signaling	NULL
pathways	NULL
in	NULL
human	NULL
T	NULL
lymphoid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
our	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
«	NULL
B-driven	NULL
reporter	NULL
gene	NULL
constructs	NULL
(	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
and	NULL
pNF-	NULL
27313	NULL
«	NULL
kB-LUC	NULL
)	NULL
and	NULL
HIV-1	NULL
LTR-based	NULL
vectors	NULL
(	NULL
pLTR-LUC	NULL
and	NULL
pm	NULL
«	NULL
BLTR-LUC	NULL
)	NULL
,	NULL
furthermore	NULL
,	NULL
suggest	NULL
that	NULL
NF-	NULL
«	NULL
B-binding	NULL
regions	NULL
and	NULL
another	NULL
element	NULL
(	NULL
s	NULL
)	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR-dependent	NULL
transcription	NULL
induced	NULL
by	NULL
PGE	NULL
,	NULL
,	NULL
.	NULL

NFAT	NULL
is	NULL
an	NULL
immediate-early	NULL
activation	NULL
factor	NULL
that	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
T-cell	NULL
activation	NULL
and	NULL
commitment	NULL
processes	NULL
through	NULL
its	NULL
control	NULL
of	NULL
IL-2	NULL
gene	NULL
activation	NULL
(	NULL
84	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
demonstrated	NULL
synergistic	NULL
effect	NULL
between	NULL
NFAT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
HIV-1	NULL
transcription	NULL
(	NULL
67	NULL
)	NULL
and	NULL
the	NULL
proposed	NULL
PGE	NULL
,	NULL
-induced	NULL
NF-	NULL
«	NULL
B-independent	NULL
pathway	NULL
,	NULL
we	NULL
looked	NULL
at	NULL
the	NULL
putative	NULL
role	NULL
of	NULL
NFAT	NULL
in	NULL
the	NULL
effect	NULL
of	NULL
PGE	NULL
.	NULL

We	NULL
found	NULL
that	NULL
NFAT	NULL
was	NULL
not	NULL
involved	NULL
in	NULL
PGE	NULL
,	NULL
-dependent	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
luciferase	NULL
activity	NULL
.	NULL

These	NULL
data	NULL
were	NULL
expected	NULL
considering	NULL
that	NULL
PGE	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
inhibit	NULL
NFAT	NULL
activity	NULL
(	NULL
85	NULL
)	NULL
.	NULL

PGE	NULL
,	NULL
could	NULL
have	NULL
the	NULL
capacity	NULL
to	NULL
modulate	NULL
several	NULL
signal	NULL
transduction	NULL
pathways	NULL
through	NULL
its	NULL
effect	NULL
on	NULL
transcription	NULL
factors	NULL
regulated	NULL
by	NULL
cAMP	NULL
such	NULL
as	NULL
the	NULL
cAMP	NULL
response-element	NULL
binding	NULL
factor	NULL
,	NULL
the	NULL
activating	NULL
protein-1	NULL
(	NULL
38	NULL
)	NULL
,	NULL
and	NULL
Spl	NULL
(	NULL
86	NULL
)	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
these	NULL
three	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
observed	NULL
NF-	NULL
«	NULL
B-independent	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
mediated	NULL
by	NULL
PGE	NULL
,	NULL
is	NULL
currently	NULL
under	NULL
investigation	NULL
.	NULL

Finally	NULL
,	NULL
by	NULL
Northern	NULL
blot	NULL
assays	NULL
,	NULL
flow	NULL
cytometric	NULL
analyses	NULL
,	NULL
and	NULL
pharmacological	NULL
studies	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
studied	NULL
T	NULL
lymphoid	NULL
cell	NULL
lines	NULL
(	NULL
Jurkat	NULL
E6.1	NULL
and	NULL
1G5	NULL
)	NULL
express	NULL
the	NULL
EP	NULL
,	NULL
receptor	NULL
subtype	NULL
on	NULL
their	NULL
surfaces	NULL
and	NULL
that	NULL
EP	NULL
,	NULL
,	NULL
EP	NULL
,	NULL
,	NULL
and	NULL
EP	NULL
;	NULL
,	NULL
receptors	NULL
seem	NULL
not	NULL
to	NULL
be	NULL
expressed	NULL
(	NULL
Figs	NULL
.	NULL

7	NULL
and	NULL
8	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
in	NULL
accord	NULL
with	NULL
previous	NULL
studies	NULL
that	NULL
have	NULL
found	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
that	NULL
the	NULL
EP	NULL
,	NULL
gene	NULL
is	NULL
expressed	NULL
on	NULL
T	NULL
lymphoid	NULL
cells	NULL
such	NULL
as	NULL
Molt-4	NULL
,	NULL
KM-3	NULL
,	NULL
and	NULL
Jurkat	NULL
E6.1	NULL
(	NULL
87-89	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
EP	NULL
,	NULL
receptors	NULL
are	NULL
coupled	NULL
to	NULL
adenylate	NULL
cyclase	NULL
via	NULL
a	NULL
stimulatory	NULL
G	NULL
protein	NULL
(	NULL
G.	NULL
,	NULL
)	NULL
and	NULL
that	NULL
such	NULL
activation	NULL
results	NULL
in	NULL
an	NULL
enhancement	NULL
of	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
(	NULL
53	NULL
,	NULL
68	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
PGE	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
lead	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
partly	NULL
via	NULL
the	NULL
EP	NULL
,	NULL
receptor	NULL
(	NULL
90	NULL
)	NULL
,	NULL
a	NULL
finding	NULL
which	NULL
lend	NULL
credence	NULL
to	NULL
the	NULL
potential	NULL
implication	NULL
of	NULL
the	NULL
EP	NULL
,	NULL
receptor	NULL
in	NULL
the	NULL
PGE	NULL
,	NULL
-induced	NULL
up-regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
.	NULL

Because	NULL
of	NULL
their	NULL
intrinsic	NULL
intracellular	NULL
obligatory	NULL
parasitic	NULL
form	NULL
of	NULL
life	NULL
,	NULL
viruses	NULL
depend	NULL
heavily	NULL
on	NULL
cell	NULL
metabolic	NULL
machinery	NULL
for	NULL
their	NULL
replication	NULL
.	NULL

Thus	NULL
,	NULL
changes	NULL
in	NULL
cellular	NULL
metabolism	NULL
might	NULL
influence	NULL
the	NULL
viral	NULL
life	NULL
cycle	NULL
.	NULL

The	NULL
experiments	NULL
reported	NULL
here	NULL
highlight	NULL
the	NULL
positive	NULL
action	NULL
of	NULL
PGE	NULL
,	NULL
a	NULL
powerful	NULL
cAMP-inducing	NULL
agent	NULL
,	NULL
on	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
HIV-1	NULL
.	NULL

The	NULL
presented	NULL
data	NULL
suggest	NULL
that	NULL
elevated	NULL
levels	NULL
of	NULL
PGE	NULL
,	NULL
detected	NULL
in	NULL
HIV-1-infected	NULL
persons	NULL
or	NULL
induced	NULL
by	NULL
opportunistic	NULL
pathogens	NULL
might	NULL
actively	NULL
participate	NULL
to	NULL
immunological	NULL
disturbances	NULL
associated	NULL
with	NULL
AIDS	NULL
and	NULL
modify	NULL
the	NULL
pathogenesis	NULL
of	NULL
this	NULL
retroviral	NULL
disease	NULL
by	NULL
inducing	NULL
a	NULL
higher	NULL
viral	NULL
load	NULL
.	NULL

Finally	NULL
,	NULL
high	NULL
concentrations	NULL
of	NULL
PGE	NULL
,	NULL
(	NULL
up	NULL
to	NULL
100	NULL
pmt	NULL
)	NULL
found	NULL
in	NULL
seminal	NULL
fluids	NULL
of	NULL
HIV-l-infected	NULL
persons	NULL
might	NULL
directly	NULL
enhance	NULL
virus	NULL
replication	NULL
and	NULL
facilitate	NULL
viral	NULL
transmission	NULL
during	NULL
sexual	NULL
activities	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
K.	NULL
L.	NULL
Calame	NULL
for	NULL
pLTRLUC	NULL
and	NULL
pme	NULL
«	NULL
BLTLUC	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
for	NULL
NFAT-LUC	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
for	NULL
p	NULL
«	NULL
B-TATA-LUC	NULL
.	NULL

We	NULL
are	NULL
indebted	NULL
to	NULL
S.	NULL
G.	NULL
Lister	NULL
for	NULL
AH	NULL
23848B	NULL
,	NULL
K.	NULL
M.	NULL
Kedzie	NULL
for	NULL
hEP	NULL
,	NULL
cDNA	NULL
,	NULL
and	NULL
M.	NULL
Abramovitz	NULL
for	NULL
hEP	NULL
,	NULL
,	NULL
hEP	NULL
;	NULL
,	NULL
and	NULL
hEP	NULL
,	NULL
cDNAs	NULL
.	NULL

The	NULL
following	NULL
items	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
NIH	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
:	NULL
1G5	NULL
and	NULL
Jurkat	NULL
E6.1	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Salim	NULL
Bounou	NULL
for	NULL
technical	NULL
assistance	NULL
in	NULL
flow	NULL
cytometry	NULL
studies	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

57	NULL
,	NULL
183-289	NULL
2	NULL
.	NULL

Margolick	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Volkman	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

188	NULL
,	NULL
1719-1723	NULL
3	NULL
.	NULL

Chowdhury	NULL
,	NULL
M.	NULL
I.	NULL
H.	NULL
,	NULL
Koyanagi	NULL
,	NULL
Y.	NULL
,	NULL
Kobayashi	NULL
,	NULL
N.	NULL
,	NULL
Yamamoto	NULL
,	NULL
N.	NULL
,	NULL
Munakata	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Lancet	NULL
386	NULL
,	NULL
247-248	NULL
4	NULL
.	NULL

Bernier	NULL
,	NULL
R.	NULL
,	NULL
Barbeau	NULL
,	NULL
B.	NULL
,	NULL
Olivier	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Tremblay	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

79	NULL
,	NULL
1353-1361	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
27314	NULL
5	NULL
.	NULL

6	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

18	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38.	NULL
.	NULL

Hui	NULL
,	NULL
R.	NULL
,	NULL
Curtis	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Sumner	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Shears	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Glasgow	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
and	NULL
Eling	NULL
,	NULL
40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

Harada	NULL
,	NULL
S.	NULL
,	NULL
Koyokani	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Yamamoto	NULL
,	NULL
N.	NULL
(	NULL
1985	NULL
)	NULL
Science	NULL
229	NULL
,	NULL
563-566	NULL
Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Phelps	NULL
,	NULL
W.	NULL
,	NULL
Feigenbaum	NULL
,	NULL
L.	NULL
,	NULL
Ostrove	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Adachi	NULL
,	NULL
A.	NULL
,	NULL
Howley	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Khoury	NULL
,	NULL
G.	NULL
,	NULL
Ginsberg	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
9759-9768	NULL
.	NULL

Bernier	NULL
,	NULL
R.	NULL
,	NULL
Turco	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Olivier	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Tremblay	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
7282-7285	NULL
.	NULL

Bernier	NULL
,	NULL
R.	NULL
,	NULL
Barbeau	NULL
,	NULL
B.	NULL
,	NULL
Tremblay	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Olivier	NULL
,	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
2881-2888	NULL
.	NULL

Goodwin	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Webb	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1980	NULL
)	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

15	NULL
,	NULL
106-122	NULL
Goodwin	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Ceuppens	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
295-315	NULL
Kurland	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Bockman	NULL
,	NULL
R.	NULL
(	NULL
1978	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

147	NULL
,	NULL
952-957	NULL
Phipps	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Illig	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Schad	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Bhimani	NULL
,	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

43	NULL
,	NULL
271-278	NULL
Heinen	NULL
,	NULL
E.	NULL
,	NULL
Cormann	NULL
,	NULL
N.	NULL
,	NULL
Braun	NULL
,	NULL
M.	NULL
,	NULL
Kinet-Denoel	NULL
,	NULL
C.	NULL
,	NULL
Vanderschelden	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Simar	NULL
,	NULL
L.	NULL
J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Ann	NULL
.	NULL

Inst	NULL
.	NULL

Pasteur	NULL
Immunol	NULL
.	NULL

187D	NULL
,	NULL
369-882	NULL
Frey	NULL
,	NULL
J.	NULL
,	NULL
Janes	NULL
,	NULL
M.	NULL
,	NULL
Eugerhardt	NULL
,	NULL
W.	NULL
,	NULL
Afting	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
Geerds	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Moller	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

158	NULL
,	NULL
85-89	NULL
Phipps	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Roper	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
Stein	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

117	NULL
,	NULL
185-158	NULL
Reiner	NULL
,	NULL
N.	NULL
E.	NULL
,	NULL
and	NULL
Malemud	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Cell	NULL
Immunol	NULL
.	NULL

184	NULL
,	NULL
556-563	NULL
Farrell	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Kirkpatrick	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

188	NULL
,	NULL
902-907	NULL
Wang	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Chadee	NULL
,	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

68	NULL
,	NULL
1089-1094	NULL
Wang	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Chadee	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Immunology	NULL
76	NULL
,	NULL
242-250	NULL
Kernacki	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Berk	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Ocul	NULL
.	NULL

Pharmacol	NULL
.	NULL

10	NULL
,	NULL
281-288	NULL
Sorrell	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
Rochester	NULL
,	NULL
C.	NULL
P.	NULL
,	NULL
Breen	NULL
,	NULL
F.	NULL
N.	NULL
,	NULL
and	NULL
Muller	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Immunol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

67	NULL
,	NULL
169-176	NULL
Onta	NULL
,	NULL
T.	NULL
,	NULL
Sashida	NULL
,	NULL
M.	NULL
,	NULL
Fijii	NULL
,	NULL
N.	NULL
,	NULL
Sugawara	NULL
,	NULL
S.	NULL
,	NULL
Rikiishi	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Kumagai	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

87	NULL
,	NULL
578-582	NULL
Rastogi	NULL
,	NULL
N.	NULL
,	NULL
Bachelet	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Carvalho-de-Sousa	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
FEMS	NULL
Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

4	NULL
,	NULL
278-279	NULL
Ben-Hur	NULL
,	NULL
T.	NULL
,	NULL
Rosenthal	NULL
,	NULL
J.	NULL
,	NULL
Itzik	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Weidenfeld	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Neurovirol	NULL
.	NULL

2	NULL
,	NULL
279-288	NULL
Henke	NULL
,	NULL
A.	NULL
,	NULL
Spengler	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Stelzner	NULL
,	NULL
A.	NULL
,	NULL
Nain	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Gemsa	NULL
,	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Res	NULL
.	NULL

Immunol	NULL
.	NULL

148	NULL
,	NULL
65-70	NULL
Midulla	NULL
,	NULL
F.	NULL
,	NULL
Huang	NULL
,	NULL
Y.	NULL
T.	NULL
,	NULL
Gilbert	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
,	NULL
Cirino	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
McFadden	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Panuska	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

140	NULL
,	NULL
771-777	NULL
Abel	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
McSharry	NULL
,	NULL
C.	NULL
,	NULL
Galloway	NULL
,	NULL
E.	NULL
,	NULL
Ross	NULL
,	NULL
C.	NULL
,	NULL
Severn	NULL
,	NULL
A.	NULL
,	NULL
Toner	NULL
,	NULL
G.	NULL
,	NULL
Gruer	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Wilkinson	NULL
,	NULL
P.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
FEMS	NULL
Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
317-323	NULL
Foley	NULL
,	NULL
P.	NULL
,	NULL
Kazazi	NULL
,	NULL
F.	NULL
,	NULL
Biti	NULL
,	NULL
R.	NULL
,	NULL
Sorrell	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
and	NULL
Cunningham	NULL
,	NULL
A.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Immunology	NULL
45	NULL
,	NULL
891-897	NULL
Griffin	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Wesselingh	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
McArthur	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Arn	NULL
.	NULL

Neurol	NULL
.	NULL

85	NULL
,	NULL
592-597	NULL
Ramis	NULL
,	NULL
I.	NULL
,	NULL
Rosello-Catafau	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Gelpi	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Chromatogr	NULL
.	NULL

575	NULL
,	NULL
148-146	NULL
Goodwin	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Bankhurst	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Messner	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1977	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

146	NULL
,	NULL
1719-1734	NULL
Goodwin	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Bankhurst	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
Messner	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
295-301	NULL
Walker	NULL
,	NULL
C.	NULL
,	NULL
Kristensen	NULL
,	NULL
F.	NULL
,	NULL
Bettens	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
de	NULL
Weck	NULL
,	NULL
A.	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

130	NULL
,	NULL
1770-1773	NULL
Rapaport	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
and	NULL
Dodge	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

155	NULL
,	NULL
948-948	NULL
Rincon	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Tugores	NULL
,	NULL
A.	NULL
,	NULL
Lopez-Rivas	NULL
,	NULL
A.	NULL
,	NULL
Silva	NULL
,	NULL
A.	NULL
,	NULL
Alonso	NULL
,	NULL
M.	NULL
,	NULL
Delandazuri	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
and	NULL
Lopez-Botet	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

18	NULL
,	NULL
1791-1796	NULL
Fedyk	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
and	NULL
Phipps	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Na	NULL
#	NULL
l	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
10978-10983	NULL
Roper	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
Phipps	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
Adv	NULL
.	NULL

Prostaglandin	NULL
Thromboxane	NULL
Leukotriene	NULL
Res	NULL
.	NULL

22	NULL
,	NULL
101-111	NULL
Haraguchi	NULL
,	NULL
S.	NULL
,	NULL
Good	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Day	NULL
,	NULL
N.	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
16	NULL
,	NULL
595-603	NULL
T.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
8020-8026	NULL
Wahl	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Corcoran	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Pyle	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Arthur	NULL
,	NULL
L.	NULL
O.	NULL
,	NULL
Harel-Bellan	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Farrar	NULL
,	NULL
W.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
621-625	NULL
Pinter	NULL
,	NULL
A.	NULL
,	NULL
Honnen	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Tilley	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Bona	NULL
,	NULL
C.	NULL
,	NULL
Zaghouani	NULL
,	NULL
H.	NULL
,	NULL
Gorny	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
and	NULL
Zolla-Pazner	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

68	NULL
,	NULL
2674-2679	NULL
Coleman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Smith	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
and	NULL
Narumiya	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Pharmacol	NULL
.	NULL

Rev	NULL
.	NULL

46	NULL
,	NULL
205-229	NULL
Kuno	NULL
,	NULL
S.	NULL
,	NULL
Ueno	NULL
,	NULL
R.	NULL
,	NULL
Hayaishi	NULL
,	NULL
O.	NULL
,	NULL
Nakashima	NULL
,	NULL
H.	NULL
,	NULL
Harada	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Yamamoto	NULL
,	NULL
N.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
3487-3490	NULL
.	NULL

Aguilar-Cordova	NULL
,	NULL
E.	NULL
,	NULL
Chinen	NULL
,	NULL
J.	NULL
,	NULL
Donehower	NULL
,	NULL
L.	NULL
,	NULL
Lewis	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
Belmont	NULL
,	NULL
J.	NULL
W.	NULL
(	NULL
1994	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
10	NULL
,	NULL
295-301	NULL
Henderson	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Zou	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Calame	NULL
,	NULL
K.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
5337-5344	NULL
Sun	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Elwood	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
1058-1065	NULL
Yasui	NULL
,	NULL
H.	NULL
,	NULL
Butscher	NULL
,	NULL
W.	NULL
,	NULL
Cohen	NULL
,	NULL
M.	NULL
,	NULL
Spriggs	NULL
,	NULL
N.	NULL
,	NULL
Wersto	NULL
,	NULL
R.	NULL
,	NULL
Kohn	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Liotta	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Gardner	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
28762-28770	NULL
48	NULL
49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

TL	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

81	NULL
.	NULL

82	NULL
.	NULL

83	NULL
.	NULL

86	NULL
.	NULL

87	NULL
.	NULL

88	NULL
.	NULL

89	NULL
.	NULL

90	NULL
.	NULL

Activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
Activity	NULL
by	NULL
PGE	NULL
,	NULL
.	NULL

Bérubé	NULL
,	NULL
P.	NULL
,	NULL
Barbeau	NULL
,	NULL
B.	NULL
,	NULL
Cantin	NULL
,	NULL
R.	NULL
,	NULL
Sékaly	NULL
,	NULL
R.-P.	NULL
,	NULL
and	NULL
Tremblay	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
4009-4016	NULL
Barbeau	NULL
,	NULL
B.	NULL
,	NULL
Bernier	NULL
,	NULL
R.	NULL
,	NULL
Dumais	NULL
,	NULL
N.	NULL
,	NULL
Briand	NULL
,	NULL
G.	NULL
,	NULL
Olivier	NULL
,	NULL
M.	NULL
,	NULL
Faure	NULL
,	NULL
R.	NULL
,	NULL
Posner	NULL
,	NULL
B.	NULL
I.	NULL
,	NULL
and	NULL
Tremblay	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
12968-12977	NULL
Andrews	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
and	NULL
Faller	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1990	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
,	NULL
2499-2500	NULL
Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Sacchi	NULL
,	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162	NULL
,	NULL
156-159	NULL
Chomezynski	NULL
,	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
BioTechniques	NULL
15	NULL
,	NULL
582-536	NULL
Nishigaki	NULL
,	NULL
N.	NULL
,	NULL
Negishi	NULL
,	NULL
M.	NULL
,	NULL
Honda	NULL
,	NULL
A.	NULL
,	NULL
Sugimoto	NULL
,	NULL
Y.	NULL
,	NULL
Namba	NULL
,	NULL
T.	NULL
,	NULL
Narumiya	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Ichikawa	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

864	NULL
,	NULL
339-341	NULL
Stenson	NULL
,	NULL
W.	NULL
F.	NULL
,	NULL
and	NULL
Parker	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
in	NULL
Prostaglandins	NULL
(	NULL
Lee	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
eds	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

89-89	NULL
,	NULL
North	NULL
Holland	NULL
,	NULL
Elsevier	NULL
,	NULL
New	NULL
York	NULL
Meade	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Smith	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
and	NULL
De	NULL
Witt	NULL
,	NULL
D.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
6610-6614	NULL
Hidaka	NULL
,	NULL
H.	NULL
,	NULL
Inagaki	NULL
,	NULL
M.	NULL
,	NULL
Kawamoto	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Susaki	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Biochemistry	NULL
28	NULL
,	NULL
5036-5041	NULL
Correia-de-Sa	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Ribeiro	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

271	NULL
,	NULL
349-355	NULL
Lippe	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Ardizzone	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Comp	NULL
.	NULL

Biochem	NULL
.	NULL

Physiol	NULL
.	NULL

99	NULL
,	NULL
209-211	NULL
Guellaen	NULL
,	NULL
G.	NULL
,	NULL
Mahu	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Mavier	NULL
,	NULL
P.	NULL
,	NULL
Berthelot	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Hanonne	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
484	NULL
,	NULL
465-475	NULL
Beavo	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Rogers	NULL
,	NULL
N.	NULL
L.	NULL
,	NULL
Crofford	NULL
,	NULL
O	NULL
.	NULL

B.	NULL
,	NULL
Hardman	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Sutherland	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
and	NULL
Newman	NULL
,	NULL
E.	NULL
V.	NULL
(	NULL
1970	NULL
)	NULL
Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

6	NULL
,	NULL
597-603	NULL
Nokta	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Pollard	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Virology	NULL
181	NULL
,	NULL
211-217	NULL
Nokta	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Pollard	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
8	NULL
,	NULL
1255-1261	NULL
Harrison	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Bers	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
925	NULL
,	NULL
188-143	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
649-681	NULL
Nabel	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
HIV	NULL
Adv	NULL
.	NULL

Res	NULL
.	NULL

Therapy	NULL
4	NULL
,	NULL
1-9	NULL
Bassuk	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Anandappa	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
and	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
3563-3573	NULL
Kinoshita	NULL
,	NULL
S.	NULL
,	NULL
Su	NULL
,	NULL
L.	NULL
,	NULL
Amano	NULL
,	NULL
M.	NULL
,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Kaneshima	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
(	NULL
1997	NULL
)	NULL
Immunity	NULL
6	NULL
,	NULL
285-244	NULL
Coleman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Eglen	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Jones	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Naramiya	NULL
,	NULL
S.	NULL
,	NULL
Shimizu	NULL
,	NULL
T.	NULL
,	NULL
Smith	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
Dahlen	NULL
,	NULL
S.	NULL
E.	NULL
M.	NULL
,	NULL
Drazen	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Gardiner	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Jackson	NULL
,	NULL
W.	NULL
T.	NULL
,	NULL
Jones	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
Krell	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
and	NULL
Nicosia	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Adv	NULL
.	NULL

Prostaglandin	NULL
Thromboxane	NULL
Leukotriene	NULL
Res	NULL
.	NULL

28	NULL
,	NULL
283-285	NULL
Hofmann	NULL
,	NULL
B.	NULL
,	NULL
Nishinian	NULL
,	NULL
P.	NULL
,	NULL
Nguyen	NULL
,	NULL
T.	NULL
,	NULL
Lin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Fayer	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
AIDS	NULL
7	NULL
,	NULL
659-664	NULL
Schnittman	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Psallidopoulos	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Lane	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Thompson	NULL
,	NULL
L.	NULL
,	NULL
Baseler	NULL
,	NULL
M.	NULL
,	NULL
Massari	NULL
,	NULL
F.	NULL
,	NULL
Fox	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Salzman	NULL
,	NULL
N.	NULL
P.	NULL
,	NULL
and	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
245	NULL
,	NULL
305-308	NULL
Fu	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
Masferrer	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Seibert	NULL
,	NULL
K.	NULL
,	NULL
Raz	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Needlman	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
16737-16740	NULL
Auberger	NULL
,	NULL
P.	NULL
,	NULL
Didier	NULL
,	NULL
M.	NULL
,	NULL
Aussel	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Fehlmann	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
.	NULL

Signalling	NULL
1	NULL
,	NULL
289-294	NULL
Goldyne	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
and	NULL
Rea	NULL
,	NULL
L.	NULL
(	NULL
1987	NULL
)	NULL
Prostaglandins	NULL
84	NULL
,	NULL
783-795	NULL
.	NULL

Kammer	NULL
,	NULL
G.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
9	NULL
,	NULL
222-229	NULL
Koh	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Yang	NULL
,	NULL
K.-H.	NULL
,	NULL
and	NULL
Kaminski	NULL
,	NULL
N.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

206	NULL
,	NULL
703-709	NULL
Baker	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Fahey	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Cell	NULL
Immunol	NULL
.	NULL

61	NULL
,	NULL
56-61	NULL
Lingk	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Chan	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Gelfand	NULL
,	NULL
E.	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

145	NULL
,	NULL
449-455	NULL
Munoz	NULL
,	NULL
E.	NULL
,	NULL
Zubiaga	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Merrow	NULL
,	NULL
M.	NULL
,	NULL
Sauter	NULL
,	NULL
N.	NULL
P.	NULL
,	NULL
and	NULL
Huber	NULL
,	NULL
B.	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
95-103	NULL
Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
826	NULL
,	NULL
711-713	NULL
Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Fransozo	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Brown	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

10	NULL
,	NULL
405-455	NULL
Muroi	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Suzuki	NULL
,	NULL
T.	NULL
(	NULL
1998	NULL
)	NULL
Cell	NULL
.	NULL

Signalling	NULL
5	NULL
,	NULL
289-298	NULL
Frantz	NULL
,	NULL
B.	NULL
,	NULL
Nordby	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Bren	NULL
,	NULL
G.	NULL
,	NULL
Steffan	NULL
,	NULL
N.	NULL
,	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
O'Keefe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

18	NULL
,	NULL
861-870	NULL
Zhong	NULL
,	NULL
H.	NULL
,	NULL
Su	NULL
Yang	NULL
,	NULL
H.	NULL
,	NULL
Erdjument-Bromage	NULL
,	NULL
H.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Ghosh	NULL
,	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
Cell	NULL
89	NULL
,	NULL
413-424	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
855-361	NULL
.	NULL

Li	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Handschumacher	NULL
,	NULL
R.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

219	NULL
,	NULL
96-99	NULL
Rohilff	NULL
,	NULL
C.	NULL
,	NULL
Ahmad	NULL
,	NULL
S.	NULL
,	NULL
Borellini	NULL
,	NULL
F.	NULL
,	NULL
Lei	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Glazer	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
21187-21141	NULL
De	NULL
Vries	NULL
,	NULL
G.	NULL
W.	NULL
,	NULL
Guarino	NULL
,	NULL
P.	NULL
,	NULL
McLaughlin	NULL
,	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
,	NULL
Andrews	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Woodward	NULL
,	NULL
D.	NULL
F.	NULL
(	NULL
1995	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

115	NULL
,	NULL
1231-1234	NULL
Mori	NULL
,	NULL
K.	NULL
,	NULL
Tanaka	NULL
,	NULL
L.	NULL
,	NULL
Kotani	NULL
,	NULL
M.	NULL
,	NULL
Miyaoka	NULL
,	NULL
F.	NULL
,	NULL
Sando	NULL
,	NULL
T.	NULL
,	NULL
Muro	NULL
,	NULL
S.	NULL
,	NULL
Sasaki	NULL
,	NULL
Y.	NULL
,	NULL
Nakagawa	NULL
,	NULL
O.	NULL
,	NULL
Ogawa	NULL
,	NULL
Y.	NULL
,	NULL
Usui	NULL
,	NULL
T.	NULL
,	NULL
Ozaki	NULL
,	NULL
S.	NULL
,	NULL
Ichikawa	NULL
,	NULL
A.	NULL
,	NULL
Narumiya	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Nakao	NULL
,	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Med	NULL
.	NULL

74	NULL
,	NULL
333-336	NULL
Blaschke	NULL
,	NULL
V.	NULL
,	NULL
Jungermann	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Piischel	NULL
,	NULL
G.	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
FEBS	NULL
Left	NULL
.	NULL

894	NULL
,	NULL
39-43	NULL
Rodbell	NULL
,	NULL
M.	NULL
(	NULL
1980	NULL
)	NULL
Nature	NULL
284	NULL
,	NULL
17-22	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Prostaglandin	NULL
Eo	NULL
Up-regulates	NULL
HIV-1	NULL
Long	NULL
Terminal	NULL
Repeat-driven	NULL
Gene	NULL
Activity	NULL
in	NULL
T	NULL
Cells	NULL
via	NULL
NF-	NULL
<	NULL
B-dependent	NULL
and	NULL
-Independent	NULL
Signaling	NULL
Pathways	NULL
Nancy	NULL
Dumais	NULL
,	NULL
Benoit	NULL
Barbeau	NULL
,	NULL
Martin	NULL
Olivier	NULL
and	NULL
Michel	NULL
J.	NULL
Tremblay	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1998	NULL
,	NULL
273:27306-27314.	NULL
doi	NULL
:	NULL
10.1074/jb0.273.42.27306	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/273/42/27306	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
89	NULL
references	NULL
,	NULL
30	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

